var title_f22_29_22992="Pityriasis alba 2";
var content_f22_29_22992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis alba",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pityriasis alba. Hypopigmented, slightly scaly macules are present on this child's cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_22992=[""].join("\n");
var outline_f22_29_22992=null;
var title_f22_29_22993="Anterior chamber granuloma";
var content_f22_29_22993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Anterior chamber granuloma due to ocular TB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) Anterior chamber granuloma with granulomatous keratic precipitates and hypopyon. Aspiration of the granuloma demonstrated acid fast bacilli in Ziehl-Neelsen stain.",
"    <br/>",
"    (Panel B) Following antituberculous treatment, the posterior segment demonstrates healed pigmented scars along the vasculature.",
"    <div class=\"footnotes\">",
"     TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_22993=[""].join("\n");
var outline_f22_29_22993=null;
var title_f22_29_22994="The Schilling test";
var content_f22_29_22994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The Schilling test (part one)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Step 1:",
"    </strong>",
"    One &micro;g of radioactive crystalline B12 is taken orally.",
"    <strong>",
"     Step 2:",
"    </strong>",
"    Gastric acid and pepsin free vitamin B12 from food proteins. This step is not required when crystalline B12 is utilized as the test dose. B12 attaches to \"R\" binders (R) produced by the stomach, which have a higher affinity for B12 than intrinsic factor (IF), also produced by the stomach.",
"    <strong>",
"     Step 3:",
"    </strong>",
"    Pancreatic proteases degrade the \"R\" binders, allowing formation of the B12-IF complex, the specific form absorbed by the terminal ileum.",
"    <strong>",
"     Step 4:",
"    </strong>",
"    One hour after the test dose, a 1000 &micro;g \"flushing\" dose of non-radioactive B12 is given to saturate B12 binders (transcobalamines).",
"    <strong>",
"     Step 5:",
"    </strong>",
"    If present, bacteria in \"blind loops\" in the duodenum or jejunum preferentially utilize vitamin B12, allowing none to be available at the site of absorption.",
"    <strong>",
"     Step 6:",
"    </strong>",
"    With blood and tissue B12 binding sites blocked by the \"flushing\" dose, the B12/IF complex is absorbed by the terminal ileum, and the B12 is excreted in the urine (step 7), which is assayed for its content of radioactivity. The test can be repeated with the addition of missing factors (eg, intrinsic factor, pancreatic extract), or following the use of nonabsorbable antibiotics (blind loops and/or bacterial overgrowth present), or gluten-free diet (celiac disease).",
"    <br>",
"     Note: While the Schilling test is rarely used today, steps 2, 3, and 6, as described above, delineate the normal pathway for B12 absorption.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_22994=[""].join("\n");
var outline_f22_29_22994=null;
var title_f22_29_22995="Flurbiprofen (ophthalmic): Drug information";
var content_f22_29_22995=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurbiprofen (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/3/38963?source=see_link\">",
"    see \"Flurbiprofen (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/61/42962?source=see_link\">",
"    see \"Flurbiprofen (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8101431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ocufen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8101436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8101533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Ophthalmic anti-inflammatory/surgical aid:",
"     </b>",
"     Ophthalmic: Instill 1 drop every 30 minutes, beginning 2 hours prior to surgery for a total of 4 drops in each affected eye.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8101534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8101561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium [drops]: 0.03% (2.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocufen&reg;: 0.03% (2.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8101434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15893018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic use only; avoid contact of bottle tip with skin or eye.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8101452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Inhibition of intraoperative miosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8101426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flurbiprofen may be confused with fenoprofen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ocufen&reg; may be confused with Ocuflox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ocufen [U.S., Canada, and multiple international markets] may be confused with Ocupres brand name for timolol [India]; Ocupress brand name for dorzolamide [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8101461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined: Ocular: Bleeding tendency increased in ocular tissue (in conjunction with ocular surgery), burning (transient), fibrosis, hyperemia, hyphemia, irritation, miosis, mydriasis, stinging (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8101457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flurbiprofen or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8101458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin/NSAID sensitivity: Use with caution in patients with previous sensitivity to aspirin or other NSAIDs, including patients who experience bronchospasm, asthma, rhinitis, or urticaria following NSAID or aspirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding/hemostasis: May increase bleeding time associated with ocular surgery. Use with caution in patients with known bleeding tendencies or those receiving anticoagulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed healing: Healing time may be slowed or delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Post-surgical patients: To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8101501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: NSAID (Ophthalmic) may diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8101454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8101455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed following systemic administration of flurbiprofen in animal reproduction studies; therefore, flurbiprofen ophthalmic is classified as pregnancy category C. Information related to systemic absorption following topical application of the eye drops has not been located. Systemic absorption would be required in order for flurbiprofen to cross the placenta and reach the fetus. Refer to the Flurbiprofen (Systemic) monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8101456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9772311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, flurbiprofen enters breast milk. Refer to the Flurbiprofen (Systemic) monograph for details. Information related to systemic absorption following topical application of the eye drops has not been located. Systemic absorption would be required in order for flurbiprofen to enter breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8101563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Flurbiprofen Sodium Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.03% (2.5 mL): $8.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ocufen Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.03% (2.5 mL): $31.33",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Edolfene (PT);",
"     </li>",
"     <li>",
"      Flur Di Fen (TW);",
"     </li>",
"     <li>",
"      Ocufen (AU, CN, CO, DK, EC, FR, GB, IE, IT, KP, MY, PE, PH, TH, TW, VE, ZA);",
"     </li>",
"     <li>",
"      Ocuflur (AT, BE, BG, CH, CZ, DE, GR, HN, IN, PL, PT, RU);",
"     </li>",
"     <li>",
"      Tolerane (AR, PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8101505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9133 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_22995=[""].join("\n");
var outline_f22_29_22995=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101431\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101436\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101533\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101534\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896257\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896258\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101561\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101434\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15893018\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101452\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101426\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101461\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101457\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101458\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299357\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101501\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101454\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101455\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101456\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9772311\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101563\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276703\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101505\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9133\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9133|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/3/38963?source=related_link\">",
"      Flurbiprofen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/61/42962?source=related_link\">",
"      Flurbiprofen (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30008?source=related_link\">",
"      Flurbiprofen (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/35/36405?source=related_link\">",
"      Flurbiprofen (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/46/7911?source=related_link\">",
"      Flurbiprofen (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_29_22996="Ramelteon: Patient drug information";
var content_f22_29_22996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ramelteon: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     see \"Ramelteon: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F854903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rozerem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ramelteon or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you wake up in the early morning, this drug will not help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take naps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid taking this drug with high-fat meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11442 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_22996=[""].join("\n");
var outline_f22_29_22996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854903\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025201\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025203\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025202\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025207\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025208\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025210\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025205\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025206\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025211\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025212\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=related_link\">",
"      Ramelteon: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_29_22997="Promethazine, phenylephrine, and codeine: Drug information";
var content_f22_29_22997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Promethazine, phenylephrine, and codeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/26/9638?source=see_link\">",
"    see \"Promethazine, phenylephrine, and codeine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/53/43859?source=see_link\">",
"    see \"Promethazine, phenylephrine, and codeine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F214246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Phenothiazine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F214237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cough and upper respiratory symptoms:",
"     </b>",
"     Oral: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F214243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/53/43859?source=see_link\">",
"      see \"Promethazine, phenylephrine, and codeine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Cough and upper respiratory symptoms:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;2 years: Use of promethazine is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;6 years: Use of this combination is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: 2.5-5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F214238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution; consider using decreased dose.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6914835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; consider decreased dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6914836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; consider decreased dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup: Promethazine hydrochloride 6.25 mg, phenylephrine hydrochloride 5 mg, and codeine phosphate 10 mg per 5 mL (120 mL, 480 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F214248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6914837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F214230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of coughs and upper respiratory symptoms including nasal congestion associated with allergy or the common cold",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4431138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2934924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to promethazine or other phenothiazines, phenylephrine, codeine, or any component of the formulation; children &lt;6 years of age; coma; treatment of lower respiratory tract symptoms, including asthma; hypertension; peripheral vascular insufficiency; use with or within 14 days of MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2934925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Phenothiazines may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); therefore, they should be used with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Use with caution in patients with bone marrow suppression; leukopenia and agranulocytosis have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use phenylephrine with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with parkinson's disease; may have increased risk of tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with severe respiratory disease (COPD, sleep apnea); may lead to potentially fatal respiratory depression. Use contraindicated in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;ultrarapid metabolizers&rdquo;: Use caution in patients with two or more copies of the variant CYP2D6*2 allele; may have extensive conversion to morphine and thus increased opioid-mediated effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: The use of this combination in children &lt;6 years of age is contraindicated;",
"     </b>",
"     respiratory depression, including fatalities, is associated with concomitant administration of promethazine and other respiratory depressants in children. Fatalities associated with respiratory depression have also been reported with promethazine use in children &lt;2 years of age. Use with caution in atopic children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use the lowest effective dose for the shortest period of time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough control: Codeine is not recommended for use for cough control in patients with a productive cough or chronic respiratory disease. Dose should not be increased if cough does not respond; re-evaluate within 5 days for possible underlying pathology.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F214236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression). Avoid ephedra, yohimbe (may cause CNS stimulation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F214240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2934928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Codeine enters breast milk; excretion of promethazine and phenylephrine is unknown. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F214234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food or water to decrease GI upset; increase fiber intake and riboflavin in diet.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F214232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10074 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-2A8E9B1E90-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_22997=[""].join("\n");
var outline_f22_29_22997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854551\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709353\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214246\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214237\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214243\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214238\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6914835\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6914836\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214228\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214218\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214248\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6914837\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214230\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4431138\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934924\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934925\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214244\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214236\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214224\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214233\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214240\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934928\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214234\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214232\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10074\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10074|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/26/9638?source=related_link\">",
"      Promethazine, phenylephrine, and codeine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/53/43859?source=related_link\">",
"      Promethazine, phenylephrine, and codeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_29_22998="Conjugated equine estrogens (systemic): Pediatric drug information";
var content_f22_29_22998=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Conjugated equine estrogens (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/51/28472?source=see_link\">",
"    see \"Conjugated equine estrogens (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41238?source=see_link\">",
"    see \"Conjugated equine estrogens (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8090824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8090832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8090841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      C.E.S.&reg;;",
"     </li>",
"     <li>",
"      Congest;",
"     </li>",
"     <li>",
"      PMS-Conjugated Estrogens C.S.D.;",
"     </li>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10478495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Estrogen Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10479006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/51/28472?source=see_link\">",
"      see \"Conjugated equine estrogens (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Use lowest effective dose for the shortest duration possible that is consistent with an individual's treatment goals and risks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Female castration or primary ovarian failure: Oral: Cyclic regimen: 1.25 mg/day for 3 weeks, then no drug for the 4th week per cycle; repeat; titrate dose to response; use lowest effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Female hypogonadism: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer's recommendation: Cyclic regimen: 0.3-0.625 mg/day for 3 weeks, then no drug for the 4th week per cycle; titrate dose to response; use lowest effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternative dosing: 2.5-7.5 mg/day in divided doses for 20 days, off 10 days and repeat until menses occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dysfunctional uterine bleeding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stable hematocrit: Oral: 1.25 mg twice daily for 21 days; if bleeding persists after 48 hours, increase to 2.5 mg twice daily; if bleeding persists after 48 more hours, increase to 2.5 mg 4 times/day; some recommend starting at 2.5 mg 4 times/day (",
"     <b>",
"      Note:",
"     </b>",
"     Medroxyprogesterone acetate 10 mg/day is also given on days 17-21; Neistein, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternatively: Oral: 2.5-5 mg/day for 7-10 days; then decrease to 1.25 mg/day for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Unstable hematocrit: Oral, I.V.: 5 mg 2-4 times/day; if bleeding is profuse, 20-40 mg every 4 hours up to 24 hours may be used;",
"     <b>",
"      Note:",
"     </b>",
"     A progestational-weighted contraception pill should also be given (eg, Ovral&reg; 2 tablets stat and 1 tablet 4 times/day or medroxyprogesterone acetate 5-10 mg 4 times/day; Neistein, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternatively: I.M., I.V.: 25 mg every 6-12 hours until bleeding stops",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8090954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premarin&reg;: 25 mg [contains lactose 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premarin&reg;: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8090843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10479009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food or after eating to reduce GI upset; administration of dose at bedtime may decrease adverse effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Add 5 mL SWI slowly against the side of the vial and shake gently; use immediately after reconstitution. I.V.: Administer slow I.V. to avoid vascular flushing; I.M.: may be administered I.M. for dysfunctional uterine bleeding, but I.V. use is preferred (more rapid response)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8090899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS and NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with LR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, heparin with hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10478838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection: Store unreconstituted vials in the refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); if reconstituted solution is not used within a few hours, store under refrigeration; reconstituted solution is stable for 60 days when stored under refrigeration; compatible with NS, dextrose, and invert sugar solutions; not compatible with ascorbic acid, protein hydrolysate, or acidic pH",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10478499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of dysfunctional uterine bleeding, hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure), moderate to severe vasomotor symptoms of menopause; moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; palliative treatment of breast cancer in select patients; palliative treatment of androgen-dependent prostate cancer; prevention of osteoporosis in postmenopausal women;",
"     <b>",
"      Note:",
"     </b>",
"     Intravenous product is indicated for short-term use only",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8090826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Premarin&reg; may be confused with Primaxin&reg;, Provera&reg;, Remeron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral]; Strength of recommendation - strong [oral]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8090870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, headache, nervousness, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, flatulence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Leukorrhea, vaginal hemorrhage, vaginal moniliasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, leg cramps, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough increased, pharyngitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional adverse reactions reported with injection; frequency not defined: Local: injection site: Edema, pain, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, anaphylaxis, angioedema, asthma exacerbation, benign meningioma (possible growth), bloating, breast cancer, breast discharge/enlargement/tenderness, cervical secretion changes, chloasma, cholestatic jaundice, contact lens intolerance, dementia, deep vein thrombosis (DVT), dysmenorrhea, edema, endometrial cancer, endometrial hyperplasia, epilepsy exacerbation, erythema multiforme, erythema nodosum, fibrocystic breast changes, galactorrhea, gallbladder disease, glucose intolerance, gynecomastia (males), hepatic hemangiomas (enlargement), hirsutism, hypersensitivity reactions, hypertension, irritability, ischemic colitis, libido changes, melasma, MI, migraine, mood disturbances, nausea, ovarian cancer, pancreatitis, pulmonary emboli (PE), pelvic pain, porphyria exacerbation, rash, retinal vascular thrombosis, stroke, superficial venous thrombosis, thrombophlebitis, triglyceride increase, urticaria, uterine bleeding (abnormal), uterine leiomyomata (increase in size), vaginal candidiasis, vomiting, weight changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10478500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estrogens or any component; history of or current DVT or PE; recent (eg, within past year) or current arterial thromboembolic disease (eg, MI, stroke); undiagnosed vaginal bleeding; pregnancy; known, suspected, or history of breast cancer (except in select patients being treated for metastatic disease); estrogen-dependent neoplasia; liver disease or dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10478830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with asthma, epilepsy, migraines, diabetes, hypothyroidism, hypocalcemia, hypercalcemia, endometriosis, porphyria, SLE, hepatic hemangioma, history of cholestatic jaundice due to past estrogen use or pregnancy, cardiac, liver, or renal dysfunction. Estrogens may cause premature closure of the epiphyses in young individuals (with large and repeated doses over an extended period of time); may cause premature breast development in prepubertal girls or gynecomastia in boys; may induce vaginal bleeding or vaginal cornification in girls; may increase risk of ovarian cancer. May increase blood pressure; may cause fluid retention; may greatly increase triglycerides and lead to pancreatitis and other problems in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10478694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens have been reported to increase the risk of endometrial carcinoma",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding; the addition of a progestin has been shown to decrease the risk of estrogen-induced endometrial hyperplasia, a condition thought to be a precursor to endometrial cancer. Do not use estrogens (with or without progestins) for the prevention of cardiovascular disease",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; a significantly increased risk of MI, stroke, PE, DVT, and invasive breast cancer was reported in postmenopausal women receiving conjugated equine estrogens combined with medroxyprogesterone acetate (Rossouw, 2002); use of conjugated estrogens alone significantly increased the risk of stroke in postmenopausal women, but did not affect the risk of coronary heart disease (Women's Health Initiative Steering Committee, 2004); due to these risks, use estrogens (with or without progestins) at the lowest effective doses and for the shortest duration possible that is consistent with an individual's treatment goals and risks; periodic risk:benefit assessments should be conducted; discontinue estrogens immediately if MI, stroke, PE, or DVT occur; in order to minimize the risk of thromboembolism in patients receiving estrogens, other risk factors for venous thromboembolism (eg, obesity, SLE, personal or family history of venous thromboembolism) and arterial vascular disease (eg, diabetes mellitus, hypertension, tobacco use, obesity, and hypercholesterolemia) should be appropriately managed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Since estrogens may increase the risk of venous thromboembolism, discontinue therapy, if possible, at least 4-6 weeks before surgery that is associated with an increased risk of thromboembolism, or during times of prolonged immobilization. Estrogens may increase the risk of breast cancer, gallbladder disease, hypercalcemia, and retinal vascular thrombosis (discontinue estrogen therapy in patients with sudden partial or complete loss of vision, sudden onset of diplopia, proptosis, or migraine, or if eye exam reveals retinal vascular lesions or papilledema). The combined use of conjugated equine estrogens and medroxyprogesterone acetate was reported to significantly increase the risk of probable dementia in postmenopausal women; it is currently not known if these findings apply to younger women or to patients receiving estrogen alone.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8090878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8090879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10478837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Larger doses of vitamin C (eg, 1 g/day in adults) may increase the serum concentrations and adverse effects of estrogens; vitamin C supplements are not recommended, but this effect may be decreased if vitamin C supplement is given 2-3 hours after estrogen; dietary intake of folate and pyridoxine may need to be increased; grapefruit juice may possibly increase estrogen plasma concentrations and effects",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8090852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are not indicated for use during pregnancy or immediately postpartum. In general, the use of estrogen and progestin as in combination hormonal contraceptives have not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10479011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, weight, serum calcium, glucose, liver enzymes; dysfunctional uterine bleeding: Hematocrit, hemoglobin, PT; bone maturation and epiphyseal effects in young patients in whom bone growth is not complete; breast exam, mammogram, Papanicolaou smear, signs for endometrial cancer in female patients with a uterus; bone density measurement if used for prevention of osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10478839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synthesis of DNA, RNA, and various proteins in target tissues; reduces the release of gonadotropin-releasing hormone from the hypothalamus; reduces FSH and LH release from the pituitary",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10478840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral, transmucosal, transdermal: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributes throughout the body; sex hormone target organs contain higher concentrations; distributes into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Primarily bound to sex hormone-binding globulin and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, via cytochrome P450 isoenzyme CYP3A4; estradiol is converted to estrone and estriol; estrone is also converted to estriol and is converted to estradiol (",
"     <b>",
"      Note:",
"     </b>",
"     A dynamic equilibrium of metabolic interconversions between estrogens exists in the circulation); estrogens also undergo hepatic sulfate and glucuronide conjugation and enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Excreted in the urine as estradiol, estrone, estriol (major urinary metabolite), and glucuronide and sulfate conjugates",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10479013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41238?source=see_link\">",
"      see \"Conjugated equine estrogens (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit caffeine; notify physician if sudden severe headache, vomiting, disturbance of vision or speech, numbness or weakness of extremity, sharp or crushing chest pain, calf pain, shortness of breath, severe abdominal pain or mass, mental depression, or unusual bleeding occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10479014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See package insert for doses related to postmenopausal symptoms, prevention of osteoporosis in postmenopausal women, and palliative treatment of breast cancer or androgen-dependent prostate cancer in adults.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Minjarez DA and Bradshaw KD, &ldquo;Abnormal Uterine Bleeding in Adolescents,&rdquo;",
"      <i>",
"       Obstet Gynecol Clin North Am",
"      </i>",
"      , 2000, 27(1):63-78.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitan LA and Slap GB, &ldquo;Adolescent Menstrual Disorders. Update,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 2000, 84(4):851-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/29/22998/abstract-text/10928192/pubmed\" id=\"10928192\" target=\"_blank\">",
"        10928192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neistein LS,",
"      <i>",
"       Adolescent Health Care - A Practical Guide",
"      </i>",
"      , 2nd ed, Baltimore: Urban &amp; Schwarzenberg, 1991, 661-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/29/22998/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Women's Health Initiative Steering Committee, &ldquo;Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/29/22998/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15982 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_22998=[""].join("\n");
var outline_f22_29_22998=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090824\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090832\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090841\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478495\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10479006\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090954\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090843\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10479009\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090899\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478838\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478499\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090826\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090870\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478500\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478830\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478694\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090878\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090879\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478837\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090852\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10479011\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478839\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10478840\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10479013\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10479014\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15982\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15982|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/51/28472?source=related_link\">",
"      Conjugated equine estrogens (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41238?source=related_link\">",
"      Conjugated equine estrogens (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=related_link\">",
"      Conjugated equine estrogens (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17158?source=related_link\">",
"      Conjugated equine estrogens (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/30/14821?source=related_link\">",
"      Conjugated equine estrogens (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_29_22999="Posterior circulation to the brain";
var content_f22_29_22999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Posterior circulation to the brain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 496px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_22999=[""].join("\n");
var outline_f22_29_22999=null;
var title_f22_29_23000="Assessment and management of lip lacerations";
var content_f22_29_23000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment and management of lip lacerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23000/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23000/contributors\">",
"     Judd E Hollander, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23000/contributors\">",
"     Lauren N Weinberger Conlon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23000/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23000/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23000/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23000/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/29/23000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6949424\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacerations continue to be a leading cause of emergency department visits. Minor wound management should reduce the likelihood of infection and be performed to achieve minimal scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/1\">",
"     1",
"    </a>",
"    ]. It is especially critical that lip lacerations are repaired correctly to preserve the cosmetic appearance and functionality of the lip. When interacting with people, our vision is immediately directed towards the eyes and lips highlighting the aesthetic importance of lip structure. The lip also serves a critical role in speech articulation, food ingestion, and tactile sensation. Most lacerations can be repaired by the emergency clinician; however, there are rare circumstances where specialist referral may be necessary.",
"   </p>",
"   <p>",
"    When evaluating trauma to the face and lip care should be taken to evaluate the patient for other traumatic injuries and the clinician should follow Advanced Trauma Life Support (ATLS) protocol. The patient should undergo primary assessment of airway, breathing, circulation, disability and neurologic function prior to secondary survey for additional injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949438\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lip is a unique structure in the body and in cross section is composed of three layers: the mucosal layer (within the oral cavity), the middle muscular layer (orbicularis oris muscle), and the outer mucosal layer consisting of the wet vermillion (internal oral) and the dry vermillion (external oral) or the &ldquo;red lip&rdquo; (",
"    <a class=\"graphic graphic_figure graphicRef60055 \" href=\"UTD.htm?25/18/25894\">",
"     figure 1",
"    </a>",
"    ). The cosmetic outline of the lip where the facial skin meets the vermillion is referred to as the vermillion border. Aesthetically the vermillion border is crucial as light reflects at this juncture and misalignment by 1 mm will cause a noticeable scar.",
"   </p>",
"   <p>",
"    The blood supply to the lip arises from the superior and inferior labial arteries which are branches of the facial artery (",
"    <a class=\"graphic graphic_figure graphicRef71766 \" href=\"UTD.htm?1/17/1302\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lip is innervated by the infraorbital and inferior alveolar nerves which arise from the trigeminal nerve (cranial nerve V) (",
"    <a class=\"graphic graphic_figure graphicRef52850 \" href=\"UTD.htm?16/42/17065\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949445\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, lip lacerations result from isolated trauma. However, as for all trauma patients, the initial clinical assessment should focus on rapid identification of potentially fatal conditions. For victims of major trauma, there should be immediate evaluation for airway compromise (while maintaining cervical spine immobilization) including the presence of midface (LeFort) injuries and dental or jaw fractures with oral hemorrhage, impaired breathing, hemorrhagic shock, and altered level of consciousness. Systematic evaluation helps ensure that potentially life-threatening injuries are promptly detected.",
"   </p>",
"   <p>",
"    The approach to the injured child or adult is discussed in detail separately (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In victims of major trauma, lip lacerations should be assessed during a careful and organized secondary survey. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H27#H27\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Secondary survey'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949453\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should identify the following aspects of the injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traumatic force (eg, high-speed motor vehicle collision with significant likelihood of associated injuries versus fall from standing height with no other symptoms)",
"     </li>",
"     <li>",
"      Associated symptoms of head injury (eg, altered mental status, vomiting, headache) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link&amp;anchor=H18#H18\">",
"       \"Minor head trauma in infants and children\", section on 'History'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Age of wound",
"     </li>",
"     <li>",
"      Presence of tooth looseness, pain, or sensitivity to hot or cold (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation and management of dental injuries in children\", section on 'Evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H6#H6\">",
"       \"Facial trauma in adults\", section on 'History and physical examination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Jaw pain (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=see_link&amp;anchor=H8#H8\">",
"       \"Jaw fractures in children\", section on 'Clinical evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H10#H10\">",
"       \"Facial trauma in adults\", section on 'Examination of specific body parts'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Difficulty in opening and closing the mouth, suggesting displaced teeth, jaw, or facial fracture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation and management of dental injuries in children\", section on 'Evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H6#H6\">",
"       \"Facial trauma in adults\", section on 'History and physical examination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Foreign body sensation (eg, embedded tooth, glass, or gravel)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history should also include a comprehensive review of the underlying medical history (eg, diabetes mellitus, cancer, prior keloid formation), medication use (eg, immunosuppressive agents), and social habits (eg, tobacco use) that may negatively affect healing and increase the risk for a poor outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H8#H8\">",
"     \"Minor wound preparation and irrigation\", section on 'Risks for poor outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should also inquire about allergies to latex, any medications (especially local anesthetics), and the patient&rsquo;s tetanus immunization status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=see_link&amp;anchor=H19#H19\">",
"     \"Allergic reactions to local anesthetics\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link&amp;anchor=H22537779#H22537779\">",
"     \"Assessment and management of facial lacerations\", section on 'Tetanus prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949464\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound assessment should identify the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Location of the injury (",
"      <a class=\"graphic graphic_figure graphicRef60055 \" href=\"UTD.htm?25/18/25894\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Depth of the injury",
"     </li>",
"     <li>",
"      Length of the laceration in centimeters",
"     </li>",
"     <li>",
"      Whether the laceration extends through the vermillion border",
"     </li>",
"     <li>",
"      Whether the laceration passes through all layers of the lip (&ldquo;through and through&rdquo; injury)",
"     </li>",
"     <li>",
"      Presence of a foreign body",
"     </li>",
"     <li>",
"      Ongoing bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should also evaluate for the following associated injuries to the face, teeth, and jaw:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dental fractures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation and management of dental injuries in children\", section on 'Examination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H27#H27\">",
"       \"Facial trauma in adults\", section on 'Dental injury'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Loose, displaced, or missing teeth (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation and management of dental injuries in children\", section on 'Examination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H27#H27\">",
"       \"Facial trauma in adults\", section on 'Dental injury'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      LeFort fracture suggested by malocclusion, midface instability, ecchymosis over the cheek, anesthesia of the region supplied by the infraorbital nerve (upper lip, alveolar ridge, lateral nose, lower eyelid) (",
"      <a class=\"graphic graphic_figure graphicRef52850 \" href=\"UTD.htm?16/42/17065\">",
"       figure 3",
"      </a>",
"      ) or enophthalmos (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H25#H25\">",
"       \"Facial trauma in adults\", section on 'Midface'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=see_link&amp;anchor=H8#H8\">",
"       \"Nasal trauma and fractures in children\", section on 'Physical examination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Jaw fracture suggested by malocclusion, trismus (unable to open jaw more than 5 cm), pain over the temporomandibular joint, or jaw tenderness (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=see_link\">",
"       \"Jaw fractures in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H29#H29\">",
"       \"Facial trauma in adults\", section on 'Temporomandibular joint'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780679\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical features suggestive of associated injuries warrant additional studies as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Midface fractures",
"      </strong>",
"      &ndash; When suspected, visualization of fractures among the complex curves of facial bones is best achieved using computed tomography (CT). CT scans of the face should include fine cuts and both coronal and sagittal reconstructions. CT angiography may be useful if the patient has a significant or expanding facial hematoma or if injury to or dissection of the carotid artery is a concern. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H12#H12\">",
"       \"Facial trauma in adults\", section on 'Facial injury'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mandibular and dental fractures",
"      </strong>",
"      &ndash; The U-shape of the mandible and the presence of adjacent bony structures make it impossible to isolate the mandible on a flat x-ray film. Therefore, simple radiographs of the mandible are less sensitive for detecting fractures than panoramic radiographs (ie, Panorex) and can miss fractures of the condyle. If available, Panorex imaging can be used for isolated mandibular fractures, dental fractures, or fractures of the alveolar ridge. Computed tomography also accurately detects mandible fractures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H15#H15\">",
"       \"Facial trauma in adults\", section on 'Mandibular injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780687\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SUBSPECIALTY CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with an appropriate specialist (eg, plastic or maxillofacial surgeon, dentist), if available, is suggested in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crush wounds or other wounds with significant amounts of devitalized tissue",
"     </li>",
"     <li>",
"      Wounds with large defects, particularly of the upper lip",
"     </li>",
"     <li>",
"      Luxation injuries in which the teeth are extruded or laterally displaced with malocclusion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link&amp;anchor=H16#H16\">",
"       \"Evaluation and management of dental injuries in children\", section on 'Other luxation injuries'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Permanent (secondary) tooth avulsion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=see_link&amp;anchor=H13#H13\">",
"       \"Evaluation and management of dental injuries in children\", section on 'Avulsions'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mandibular fracture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=see_link&amp;anchor=H12#H12\">",
"       \"Jaw fractures in children\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      LeFort fracture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link&amp;anchor=H25#H25\">",
"       \"Facial trauma in adults\", section on 'Midface'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949471\">",
"    <span class=\"h1\">",
"     WOUND REPAIR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780704\">",
"    <span class=\"h2\">",
"     Indications for primary closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary closure (ie, wound repair at the time of presentation) is the preferred treatment for most lip lacerations.",
"   </p>",
"   <p>",
"    Delayed primary closure (ie, cleansing and debridement at the time of initial presentation with definitive wound closure performed electively four to five days later) may be appropriate for wounds of the lip that present after 24 hours",
"    <strong>",
"     and",
"    </strong>",
"    have increased risk for infection. In general, the decision should be based upon the time from injury, patient factors that increase the risk of infection (eg, vascular insufficiency or in adults, diabetes mellitus), and wound factors (bite wound, other contamination, or foreign body potential). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H10#H10\">",
"     \"Minor wound preparation and irrigation\", section on 'Type of closure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780712\">",
"    <span class=\"h2\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds with obvious signs of inflammation (redness, warmth, swelling, pus drainage) should not be closed primarily. Lip laceration repair should also",
"    <strong>",
"     not",
"    </strong>",
"    delay further evaluation and definitive care of more urgent traumatic injuries, including underlying midface or jaw injuries.",
"   </p>",
"   <p>",
"    When using delayed primary closure, saline-soaked gauze packing (wet-dry closure) can be provided to enhance secondary healing. Appropriate antibiotic coverage (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    or in penicillin-allergic patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ) aimed at the flora of the skin and possibly upper respiratory tract can be initiated in selected patients with wounds other than bite wounds (eg, patient with diabetes mellitus, or other risks for poor wound outcome), although there is no direct evidence supporting any benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H10#H10\">",
"     \"Minor wound preparation and irrigation\", section on 'Type of closure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications and empiric oral antibiotic regimens for patients with animal bites (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"     table 1",
"    </a>",
"    ) and human bites (",
"    <a class=\"graphic graphic_table graphicRef69328 \" href=\"UTD.htm?6/17/6429\">",
"     table 2",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial management of animal and human bites\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780720\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparation for the care of lip lacerations includes a discussion of the likely outcomes of repair, the choice of repair, assembly of the appropriate equipment, provision of anesthesia and analgesia,",
"    <strong>",
"    </strong>",
"    and wound debridement and cleansing. The patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    caregiver must be aware of the general risks of laceration repair, which include infection, pain and scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780728\">",
"    <span class=\"h3\">",
"     Anesthesia and analgesia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949486\">",
"    <span class=\"h4\">",
"     Regional block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional nerve blocks are the anesthetic method of choice for lip laceration repair. Direct infiltration of local anesthetic into lip lacerations should be avoided as this can distort the lip tissue, making it more difficult to complete an optimal cosmetic repair. Infraorbital (",
"    <a class=\"graphic graphic_figure graphicRef77549 \" href=\"UTD.htm?43/17/44309\">",
"     figure 5",
"    </a>",
"    ) and mental nerve blocks (",
"    <a class=\"graphic graphic_figure graphicRef64720 \" href=\"UTD.htm?35/20/36165\">",
"     figure 6",
"    </a>",
"    ) anesthetize the skin and mucosal surfaces of the upper and lower lips respectively. If the laceration crosses the midline, bilateral nerve blocks should be performed.",
"   </p>",
"   <p>",
"    The techniques for infraorbital and mental nerve blocks are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link&amp;anchor=H8983021#H8983021\">",
"     \"Assessment and management of facial lacerations\", section on 'Facial nerve blocks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonpharmacologic interventions such as the use of biobehavioral and cognitive distraction may be useful when performing regional blocks in children and other apprehensive patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1684879#H1684879\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Nonpharmacologic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780776\">",
"    <span class=\"h4\">",
"     Procedural sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedural sedation is likely to maximize patient comfort and cosmetic outcomes in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lip lacerations in young or uncooperative children that require precise approximation (eg, lacerations of the vermillion border)",
"     </li>",
"     <li>",
"      Complex lip lacerations that require extensive revision",
"     </li>",
"     <li>",
"      Highly anxious or otherwise uncooperative patients, especially when the safety of clinician and staff may be compromised",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Procedural sedation in children and adults is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949525\">",
"    <span class=\"h3\">",
"     Irrigation and debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local or regional anesthesia prior to initiating irrigation and wound cleansing improves patient comfort. In young children and patients with heavily contaminated wounds, procedural sedation may also be necessary so that wound preparation can be tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link&amp;anchor=H22537623#H22537623\">",
"     \"Assessment and management of facial lacerations\", section on 'Anesthesia and analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral and perioral wounds are contaminated wounds since saliva typically contains one million",
"    <sup>",
"    </sup>",
"    bacteria per milliliter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/2\">",
"     2",
"    </a>",
"    ]. Local wound inoculums of 100,000 bacteria per gram of tissue are sufficient to cause wound infection. Although irrigation with normal saline has not been shown to decrease rates of infection, the authors and others still perform irrigation of lip lacerations to enhance removal of gross contaminants within the wound [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The suggested volume of irrigation solution is approximately 50 to 100 mL per centimeter of laceration. Particularly in sedated patients, care should be taken to frequently perform oral suction and to maintain patients in a head-up position so that aspiration of irrigation solution is prevented.",
"   </p>",
"   <p>",
"    Antiseptics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , povidone-iodine solution (Betadine&reg;), or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , should be avoided because they are cytotoxic and can cause tissue injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of nonviable tissue increases the rate of infection after wound closure and such tissue should therefore be removed. However, debridement of lip lacerations and oral wounds should not be performed by emergency clinicians because it distorts the original architecture and alters the cosmetic appearance. The presence of crushed, devitalized or necrotic tissue is a potential indication for surgical specialty consultation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H14#H14\">",
"     \"Minor wound preparation and irrigation\", section on 'Debridement'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H22780687\">",
"     'Indications for subspecialty consultation or referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinician should not shave facial hair near the laceration because shaving is associated with the deposition of bacteria into the wound [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/4\">",
"     4",
"    </a>",
"    ]. If facial hair impedes visualization of the wound, it can be clipped with scissors or smoothed down away from the wound edge with normal saline or petrolatum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780760\">",
"    <span class=\"h3\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following equipment should be assembled for facial laceration repair: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sterile gloves",
"     </li>",
"     <li>",
"      Surgical mask",
"     </li>",
"     <li>",
"      Eye protection",
"     </li>",
"     <li>",
"      Buffered 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      (with or without epinephrine) or similar local anesthetic (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"UTD.htm?25/56/26509\">",
"       table 3",
"      </a>",
"      ) ; lidocaine with epinephrine is preferable for patients with ongoing bleeding and for most regional blocks; plain lidocaine is preferred for the patient undergoing direct infiltration so that blanching does not obscure the vermillion border",
"     </li>",
"     <li>",
"      Small volume syringe (eg, 3 or 6 mL) with small gauge needle (eg, 25 or 27 gauge) for infiltration of local anesthetic; a short needle (eg, 0.625 inch) is preferable for young children or other patients in whom movement is anticipated",
"     </li>",
"     <li>",
"      Nonabsorbable suture for skin closure (",
"      <a class=\"graphic graphic_table graphicRef63622 \" href=\"UTD.htm?36/14/37099\">",
"       table 4",
"      </a>",
"      ): 5.0 or 6.0 nonabsorbable suture (6.0 in children, absorbable suture [eg, fast-absorbing gut] avoids the need for suture removal and is especially preferred in young children)",
"     </li>",
"     <li>",
"      Absorbable suture for submucosal closure: 4.0 or 5.0 absorbable suture (5.0 in children), such as polyglactin 910 (Vicryl&reg;) or poliglecaprone 25 (Monocryl&reg;)",
"     </li>",
"     <li>",
"      Absorbable suture for muscle layer closure: 5.0 absorbable suture such as polyglactin 910 (Vicryl&reg;) or poliglecaprone 25 (Monocryl&reg;)",
"     </li>",
"     <li>",
"      Absorbable for surface mucosal closure: 5.0 or 6.0 absorbable suture (6.0 in children), chromic gut",
"     </li>",
"     <li>",
"      Needle holder",
"     </li>",
"     <li>",
"      Hemostat",
"     </li>",
"     <li>",
"      Tissue forceps",
"     </li>",
"     <li>",
"      Scissors",
"     </li>",
"     <li>",
"      Surgical probe",
"     </li>",
"     <li>",
"      Sterile 4 x 4 gauze",
"     </li>",
"     <li>",
"      Absorbent towels",
"     </li>",
"     <li>",
"      Sterile field drapes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergency departments generally are well-equipped with minor surgical or suture trays that contain the instruments, sterile gauze, towels, and drapes listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780768\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Superficial dry vermillion lacerations",
"      </strong>",
"      &ndash; Superficial lacerations of the dry vermillion (visible part of the lip when the mouth is closed (",
"      <a class=\"graphic graphic_figure graphicRef60055 \" href=\"UTD.htm?25/18/25894\">",
"       figure 1",
"      </a>",
"      )) that extend to the submucosa and do not involve the vermillion border should be closed with 5.0 or 6.0 chromic or fast-absorbing gut (6.0 in children) using simple interrupted sutures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H20#H20\">",
"       \"Closure of skin wounds with sutures\", section on 'Percutaneous skin closure'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Superficial wet vermillion lacerations",
"      </strong>",
"      &ndash; Most small, superficial lacerations of the wet vermillion (inner portion of the lip when the mouth is closed (",
"      <a class=\"graphic graphic_figure graphicRef60055 \" href=\"UTD.htm?25/18/25894\">",
"       figure 1",
"      </a>",
"      )) do",
"      <strong>",
"       not",
"      </strong>",
"      require closure.",
"      <br/>",
"      <br/>",
"      However, lacerations that have ongoing oozing of blood and that are longer than 2 centimeters or have a gaping defect or flap should be closed so that food particles do not get stuck in the wound. The clinician should repair these wounds with 5.0 or 6.0 chromic gut using deep buried stitches to avoid irritation of the gums, mucosa, and tongue and suture dislodgement (",
"      <a class=\"graphic graphic_figure graphicRef75042 \" href=\"UTD.htm?31/22/32097\">",
"       figure 7",
"      </a>",
"      ). Suture knots should be secured with at least four square knots. Nonabsorbable sutures should",
"      <strong>",
"       not",
"      </strong>",
"      be placed within the oral mucosa as they are irritating to adjacent structures. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Lacerations through the vermillion border",
"      </strong>",
"      &ndash; Precise repair of the vermillion border is essential for a good cosmetic outcome. When repairing the vermillion border, the clinician should first place a &ldquo;stay stitch&rdquo; at the vermillion border to ensure proper alignment using 6-0 nonabsorbable suture (eg, polypropylene [Prolene&reg;] or nylon [Ethilon]) (",
"      <a class=\"graphic graphic_figure graphicRef55006 \" href=\"UTD.htm?34/14/35055\">",
"       figure 8",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Once the vermillion border is approximated, simple skin lacerations should be closed with simple interrupted stitches using 5.0 or 6.0 (6.0 in children) nonabsorbable suture (eg, polypropylene [Prolene&reg;] or nylon [Ethilon]). In children and older patients for whom follow-up is not assured, skin closure may be accomplished with 6.0 fast-absorbing gut.",
"      <br/>",
"      <br/>",
"      Lacerations of the vermillion and the oral mucosa should be repaired with 5-0 or 6-0 absorbable (chromic gut) sutures as described above.",
"     </li>",
"     <li>",
"      <strong>",
"       Through and through lip lacerations",
"      </strong>",
"      &ndash; Lacerations that extend through all layers of the lip (",
"      <a class=\"graphic graphic_figure graphicRef60055 \" href=\"UTD.htm?25/18/25894\">",
"       figure 1",
"      </a>",
"      ) should be closed in stepwise fashion as follows (",
"      <a class=\"graphic graphic_figure graphicRef65733 \" href=\"UTD.htm?40/60/41926\">",
"       figure 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prepare the wound as described above. (See",
"      <a class=\"local\" href=\"#H6949525\">",
"       'Irrigation and debridement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      D&eacute;bride any obviously traumatized minor salivary glands to avoid delayed formation of a mucocele.",
"     </li>",
"     <li>",
"      Align the vermillion border using 6-0 nonabsorbable suture (eg, polypropylene [Prolene&reg;] or nylon [Ethilon]) (",
"      <a class=\"graphic graphic_figure graphicRef55006 \" href=\"UTD.htm?34/14/35055\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Close the inner fibrofatty junction with 4.0 or 5.0 absorbable suture such as polyglactin 910 (Vicryl&reg;) or poliglecaprone 25 (Monocryl&reg;) suture (5.0 in children) as shown in plate B of the figure (",
"      <a class=\"graphic graphic_figure graphicRef65733 \" href=\"UTD.htm?40/60/41926\">",
"       figure 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Reirrigate the wound from the outside.",
"     </li>",
"     <li>",
"      Close the outer fibrofatty junction with 4.0 or 5.0 absorbable suture such as polyglactin 910 (Vicryl&reg;) or poliglecaprone 25 (Monocryl&reg;) suture (5.0 in children) as shown in plate C of the figure (",
"      <a class=\"graphic graphic_figure graphicRef65733 \" href=\"UTD.htm?40/60/41926\">",
"       figure 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Identify and close any laceration to the orbicularis muscle layer located beyond the vermillion border with 5.0 absorbable suture such as polyglactin 910 (Vicryl&reg;) using deep buried sutures (",
"      <a class=\"graphic graphic_figure graphicRef75042 \" href=\"UTD.htm?31/22/32097\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Close the wet and dry vermillion as described above.",
"     </li>",
"     <li>",
"      Close the skin beyond the vermillion border with 5.0 or 6.0 (6.0 in children) using nonabsorbable suture (eg, polypropylene [Prolene&reg;] or nylon [Ethilon]). In children and older patients for whom follow-up is not assured, skin closure may be accomplished with 6.0 fast-absorbing gut. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780784\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780792\">",
"    <span class=\"h2\">",
"     Tetanus prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus prophylaxis should be provided for all wounds as indicated (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 5",
"    </a>",
"    ). Tetanus prophylaxis for pregnant women depends upon their immunization history and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780826\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with through and through lip lacerations receive prophylactic antibiotics selected to cover oral flora (eg, penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    , or in penicillin-allergic patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ). However, evidence does",
"    <strong>",
"     not",
"    </strong>",
"    support administration of antibiotics to all patients with lip lacerations, especially clean wounds that do not involve wet mucosal surfaces.",
"   </p>",
"   <p>",
"    The risk of wound infection following lip laceration varies from 9 to 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Randomized trials have not shown a significant benefit of empiric antibiotics but have enrolled low numbers of patients and have not been blinded [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/11\">",
"     11",
"    </a>",
"    ]. One study did find fewer infections in compliant patients and in patients with more extensive lacerations (eg, through and through lip lacerations) versus no treatment (0 versus 18 percent and 7 versus 27 percent, respectively) although these results were not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23000/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Taken together, the evidence suggests that antibiotics may decrease the rate of wound infection after repair of lip lacerations with significant mucosal involvement and that this is a reasonable therapy given that oral and perioral lacerations are contaminated by abundant facultative species and obligate anaerobes. However, clean lacerations that do not involve wet mucosal surfaces and occur in healthy patients do not require antibiotic prophylaxis.",
"   </p>",
"   <p>",
"    Indications and empiric oral antibiotic regimens for patients with animal bites (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"     table 1",
"    </a>",
"    ) and human bites (",
"    <a class=\"graphic graphic_table graphicRef69328 \" href=\"UTD.htm?6/17/6429\">",
"     table 2",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial management of animal and human bites\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780875\">",
"    <span class=\"h2\">",
"     Bite wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bites, scratches, abrasions, or contact with animal saliva via mucous membranes or a break in the skin all can transmit rabies. Early wound cleansing is an important prophylactic measure, in addition to timely administration of rabies immune globulin and vaccine (",
"    <a class=\"graphic graphic_table graphicRef70600 \" href=\"UTD.htm?27/43/28347\">",
"     table 6",
"    </a>",
"    ). Indications for rabies prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link&amp;anchor=H19#H19\">",
"     \"Rabies immune globulin and vaccine\", section on 'Dosing schedules and routes of administration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=see_link&amp;anchor=H8#H8\">",
"     \"When to use rabies prophylaxis\", section on 'Types of exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any unvaccinated patient or individual negative for anti-HBs antibodies who is bitten by an individual positive for HBsAg should receive both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59736 \" href=\"UTD.htm?20/39/21116\">",
"     table 7",
"    </a>",
"    ). In addition, although the risk for transmitting HIV through saliva is extremely low, infection is of concern if there is blood in the saliva. Counseling regarding post-exposure HIV prophylaxis is appropriate in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial management of animal and human bites\", section on 'Viral prophylaxis after human bites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949560\">",
"    <span class=\"h1\">",
"     AFTERCARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the wound is repaired, the clinician should apply a topical antibiotic ointment (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ) to the dry vermillion or perioral skin, as indicated. Occlusive dressings are difficult to maintain around the lip and are unnecessary.",
"   </p>",
"   <p>",
"    Some patients (eg, those with through and through lacerations or risk factors for infection) should undergo reevaluation 48 to 72 hours after repair to ensure proper healing. Patients capable of self assessment might not need physician evaluation at this time.",
"   </p>",
"   <p>",
"    Patients with intraoral lip lacerations should be advised as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eat soft foods for two to three days.",
"     </li>",
"     <li>",
"      Rinse the mouth with water after eating.",
"     </li>",
"     <li>",
"      Avoid spicy or salty foods until the wound is healed.",
"     </li>",
"     <li>",
"      Avoid the use of straws (negative pressure may increase ecchymosis or bleeding at the wound site).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonabsorbable sutures should be removed by a health care provider in three to five days, as should any simple interrupted absorbable sutures of the wet or dry vermillion that have not dissolved by five days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/51/6962?source=see_link\">",
"       \"Patient information: Stitches (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6949614\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lip is a unique structure in the body and in cross section is composed of three layers: the mucosal layer (within the oral cavity), the middle muscular layer (orbicularis oris muscle), and the outer mucosal layer consisting of the wet vermillion (internal oral) and the dry vermillion (external oral) or the &ldquo;red lip&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef60055 \" href=\"UTD.htm?25/18/25894\">",
"       figure 1",
"      </a>",
"      ). The cosmetic outline of the lip where the facial skin meets the vermillion is referred to as the vermillion border. Aesthetically the vermillion border is crucial as light reflects at this juncture and misalignment by 1 mm may cause a noticeable cosmetic defect. (See",
"      <a class=\"local\" href=\"#H6949438\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with lip lacerations require careful evaluation to determine the location and depth of the wound, whether the laceration involves the vermillion border or extends entirely through the lip, or is associated with significant trauma to the midface, dentition, or mandible. (See",
"      <a class=\"local\" href=\"#H6949445\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical specialty consultation, if available, is appropriate for crush wounds, wounds with large defects, and wounds with associated tooth avulsion, dental extrusion or lateral displacement with malocclusion, mandibular fracture, or LeFort fracture. (See",
"      <a class=\"local\" href=\"#H22780687\">",
"       'Indications for subspecialty consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary closure (ie, wound repair at the time of presentation) is the preferred treatment for most lip lacerations. Wounds with obvious signs of inflammation (redness, warmth, swelling, pus drainage) should not be closed primarily. Lip laceration repair should also",
"      <strong>",
"       not",
"      </strong>",
"      delay further evaluation and definitive care of more urgent traumatic injuries, including underlying midface or jaw injuries. (See",
"      <a class=\"local\" href=\"#H22780704\">",
"       'Indications for primary closure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22780712\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regional nerve blocks are the anesthetic method of choice for lip laceration repair. Direct infiltration of local anesthetic into lip lacerations should be avoided, as this can distort the lip tissue making it more difficult to complete an optimal cosmetic repair. Infraorbital (",
"      <a class=\"graphic graphic_figure graphicRef77549 \" href=\"UTD.htm?43/17/44309\">",
"       figure 5",
"      </a>",
"      ) and mental nerve blocks (",
"      <a class=\"graphic graphic_figure graphicRef64720 \" href=\"UTD.htm?35/20/36165\">",
"       figure 6",
"      </a>",
"      ) anesthetize the skin and mucosal surfaces of the upper and lower lips respectively. If the laceration crosses the midline, bilateral nerve blocks should be performed. (See",
"      <a class=\"local\" href=\"#H22780728\">",
"       'Anesthesia and analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral and perioral wounds are contaminated wounds. Although irrigation with normal saline has not been shown to decrease rates of infection, the authors and others still perform irrigation of lip lacerations to enhance removal of gross contaminants within the wound. The suggested volume of irrigation solution is approximately 50 to 100 mL per centimeter of laceration. Antiseptics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      , povidone-iodine solution (Betadine&reg;), or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      , should be avoided because they are cytotoxic and can cause tissue injury. The clinician should not shave facial hair near the laceration. Debridement of lip lacerations and oral wounds should not be performed by inexperienced clinicians because it distorts the original architecture and alters the cosmetic appearance. The presence of crushed, devitalized or necrotic tissue is a potential indication for surgical specialty consultation. (See",
"      <a class=\"local\" href=\"#H6949525\">",
"       'Irrigation and debridement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The suggested equipment and techniques for closure of lip lacerations are provided. (See",
"      <a class=\"local\" href=\"#H22780760\">",
"       'Equipment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22780768\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with through and through lip lacerations receive prophylactic antibiotics selected to cover oral flora (eg, penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      , or in penicillin-allergic patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Prophylactic antibiotics may also decrease the risk of wound infection in patients with animal or human bites. However, evidence does",
"      <strong>",
"       not",
"      </strong>",
"      support administration of antibiotics to all healthy patients with lip lacerations, especially those with clean wounds that do not involve wet mucosal surfaces. (See",
"      <a class=\"local\" href=\"#H22780826\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22780875\">",
"       'Bite wounds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should receive tetanus prophylaxis, as needed. (See",
"      <a class=\"local\" href=\"#H22780792\">",
"       'Tetanus prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aftercare consists of the following (see",
"      <a class=\"local\" href=\"#H6949560\">",
"       'Aftercare'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Application of topical antibiotic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      ) to external wounds",
"     </li>",
"     <li>",
"      Reevaluation in 48 to 72 hours",
"     </li>",
"     <li>",
"      Soft diet, mouth rinsing after eating, and avoidance of irritating foods or straw use in patients with intraoral lip lacerations",
"     </li>",
"     <li>",
"      Removal of nonabsorbable sutures in three to five days",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/1\">",
"      Singer AJ, Hollander JE, Quinn JV. Evaluation and management of traumatic lacerations. N Engl J Med 1997; 337:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/2\">",
"      Mantilla G&oacute;mez S, Danser MM, Sipos PM, et al. Tongue coating and salivary bacterial counts in healthy/gingivitis subjects and periodontitis patients. J Clin Periodontol 2001; 28:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/3\">",
"      Armstrong BD. Lacerations of the mouth. Emerg Med Clin North Am 2000; 18:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/4\">",
"      Grunebaum LD, Smith JE, Hoosien GE. Lip and perioral trauma. Facial Plast Surg 2010; 26:433.",
"     </a>",
"    </li>",
"    <li>",
"     Attia MW, Loiselle J. Management of soft-tissue injuries of the mouth. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds).  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, PA 2008. p.680.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/6\">",
"      GOLDBERG MH. ANTIBIOTICS AND ORAL AND ORAL-CUTANEOUS LACERATIONS. J Oral Surg 1965; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/7\">",
"      Paterson JA, Cardo VA Jr, Stratigos GT. An examination of antibiotic prophylaxis in oral and maxillofacial surgery. J Oral Surg 1970; 28:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/8\">",
"      Altieri M, Brasch L, Getson P. Antibiotic prophylaxis in intraoral wounds. Am J Emerg Med 1986; 4:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/9\">",
"      Steele MT, Sainsbury CR, Robinson WA, et al. Prophylactic penicillin for intraoral wounds. Ann Emerg Med 1989; 18:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/10\">",
"      Abubaker AO. Use of prophylactic antibiotics in preventing infection of traumatic injuries. Dent Clin North Am 2009; 53:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23000/abstract/11\">",
"      Mark DG, Granquist EJ. Are prophylactic oral antibiotics indicated for the treatment of intraoral wounds? Ann Emerg Med 2008; 52:368.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13877 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-EBA391572F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_23000=[""].join("\n");
var outline_f22_29_23000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6949614\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6949424\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6949438\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6949445\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6949453\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6949464\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780679\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22780687\">",
"      INDICATIONS FOR SUBSPECIALTY CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6949471\">",
"      WOUND REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780704\">",
"      Indications for primary closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780712\">",
"      Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780720\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22780728\">",
"      - Anesthesia and analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6949486\">",
"      Regional block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22780776\">",
"      Procedural sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6949525\">",
"      - Irrigation and debridement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22780760\">",
"      - Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780768\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22780784\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780792\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780826\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780875\">",
"      Bite wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6949560\">",
"      AFTERCARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6949614\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13877|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/18/25894\" title=\"figure 1\">",
"      Lip anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/17/1302\" title=\"figure 2\">",
"      Blood supply to the face and mouth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/42/17065\" title=\"figure 3\">",
"      Anatomic distributions of the trigeminal nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 4\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44309\" title=\"figure 5\">",
"      Infraorbital nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/20/36165\" title=\"figure 6\">",
"      Mental nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/22/32097\" title=\"figure 7\">",
"      Technique for deep suture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/14/35055\" title=\"figure 8\">",
"      Lip laceration through the vermillion border",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/60/41926\" title=\"figure 9\">",
"      Repair of through and through lip laceration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13877|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/4/37964\" title=\"table 1\">",
"      Empiric oral antibiotics animal bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/17/6429\" title=\"table 2\">",
"      Oral antibiotics human bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/56/26509\" title=\"table 3\">",
"      Comparison of commonly infiltrated local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/14/37099\" title=\"table 4\">",
"      Nonabsorbable sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 5\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/43/28347\" title=\"table 6\">",
"      Rabies postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/39/21116\" title=\"table 7\">",
"      Postexposure prophylaxis hepatitis B vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=related_link\">",
"      Allergic reactions to local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=related_link\">",
"      Assessment and management of facial lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/46/32489?source=related_link\">",
"      Evaluation and management of dental injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=related_link\">",
"      Facial trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=related_link\">",
"      Jaw fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=related_link\">",
"      Nasal trauma and fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/51/6962?source=related_link\">",
"      Patient information: Stitches (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=related_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_29_23001="Structure and function of normal human hemoglobins";
var content_f22_29_23001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Structure and function of normal human hemoglobins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23001/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23001/contributors\">",
"     Martin H Steinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23001/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23001/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23001/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/29/23001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The study of hemoglobins, both normal and mutant, has provided fundamental insights into structure-function relationships of proteins in general and, in particular, the molecular basis of oxygen transport. The discovery that sickle hemoglobin has an abnormal electrophoretic mobility began the era of molecular medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/1\">",
"     1",
"    </a>",
"    ]. With the advent of recombinant DNA technology, research on hemoglobin provided early and important information about the organization and regulation of genes as well as insights as to how ontogeny affects gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemoglobin motifs can be found in the most ancient unicellular plants and animals and have evolved over hundreds of millions of years into gas transport proteins through the processes of gene duplication, conversion, divergence, and inactivating mutation that have culminated in hemoglobin gene clusters on separate chromosomes, whose expression is developmentally regulated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/3\">",
"     3",
"    </a>",
"    ]. All human hemoglobin genes contain 3 exons separated by 2 introns; the exons may encode distinct functional domains of the molecule. The tetrameric globular structure of hemoglobin is adapted to the physiology of complex organisms and their needs for regulation of oxygen delivery far better than primitive globins like hemocyanin or erythrocruorin, and single chain globins like muscle myoglobin or the other cellular globins such as cytoglobin and neuroglobin.",
"   </p>",
"   <p>",
"    The primary amino acid structure of the constituent globin chains dictates the quaternary structure, which, in turn, is the basis of the ability of hemoglobin to rapidly bind oxygen in the lungs and unload it in the tissues. Hemoglobin function may be altered by mutation, pH, and 2,3-biphosphoglycerate (2,3-BPG, also called 2,3-diphosphoglycerate or 2,3-DPG).",
"   </p>",
"   <p>",
"    The structure and function of the various normal human hemoglobins will be discussed here. Abnormal hemoglobins are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=see_link\">",
"     \"Introduction to hemoglobin mutations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link\">",
"     \"Unstable hemoglobin variants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin is a 64.4 kd tetramer consisting of two pairs of globin polypeptide chains: one pair of alpha-like chains, and one pair of non-alpha chains. The chains are designated by Greek letters, which are used to describe the particular hemoglobin (eg, Hb A is",
"    <span class=\"nowrap\">",
"     alpha2/beta2).",
"    </span>",
"   </p>",
"   <p>",
"    Two",
"    copies of the alpha-globin gene (HBA2, HBA1) are located on chromosome 16 (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"UTD.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ) along with the embryonic zeta genes (HBZ). There is no substitute for alpha globin in the formation of any of the normal hemoglobins (Hb) following birth (eg, Hb A, Hb A2, and Hb F). Thus, absence any alpha globin, as seen when all 4 alpha-globin genes are inactive or deleted is incompatible with extrauterine life, except when extraordinary measures are taken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"     \"Pathophysiology of alpha thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A homotetramer of only alpha-globin chains is not thought to occur, but in the absence of alpha chains, beta and gamma homotetramers (HbH and Bart's hemoglobin, respectively) can be found, although they lack cooperativity and function poorly in oxygen transport. The single beta-globin gene (HBB) resides on chromosome 11, within a gene cluster consisting of an embryonic beta-like gene, the epsilon gene (HBE1), the duplicated and nearly identical fetal, or gamma globin genes (HBG2, HBG1), and the poorly expressed delta-globin gene (HBD) (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"UTD.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ). A heme group, consisting of a single molecule of protoporphyrin IX coordinately bound to a single ferrous (Fe2+) ion, is linked covalently at a specific site to each globin chain. If the iron is oxidized to the ferric state (Fe3+), the protein is called methemoglobin.",
"   </p>",
"   <p>",
"    Alpha globin chains contain 141 amino acids (residues) while the beta-like chains contain 146 amino acids. Approximately 75 percent of hemoglobin is in the form of an alpha helix. The nonhelical stretches permit folding of the polypeptide upon itself. Individual residues can be assigned to one of eight helices (A-H) or to adjacent nonhelical stretches.",
"   </p>",
"   <p>",
"    Heme iron is linked covalently to a histidine at the eighth residue of the F helix (His F8), at residue 87 of the alpha chain and residue 92 of the beta chain. Residues that have charged side groups, such as lysine, arginine, and glutamic acid, lie on the surface of the molecule in contact with the surrounding water solvent. Exposure of the hydrophilic (charged) amino acids to the aqueous milieu is an important determinant of the solubility of hemoglobin within the red blood cell and of the prevention of precipitation.",
"   </p>",
"   <p>",
"    The hemoglobin tetramer is a globular molecule (5.0 x 5.4 x 6.4 nm) with a single axis of symmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/4\">",
"     4",
"    </a>",
"    ]. The polypeptide chains are folded such that the four heme groups lie in clefts on the surface of the molecule equidistant from one another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oxygenation and deoxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygenation and deoxygenation of hemoglobin occur at the heme iron. Upon deoxygenation, the hemoglobin molecule undergoes a marked change in conformation, as the beta chains rotate apart by approximately 0.7 nm. Deoxyhemoglobin is stabilized in a constrained or tense (T) configuration by inter- and intra-subunit salt bonds. These salt bonds are responsible for the Bohr effect and for the binding of 2,3-BPG, both of which modify oxygen affinity (see below).",
"   </p>",
"   <p>",
"    Upon the addition of oxygen, the salt bonds are sequentially broken and the fully oxygenated hemoglobin is in the relaxed (R) configuration. In this state, there is less bonding energy between the subunits and the oxygenated molecule is able to dissociate reversibly, forming two alpha-beta dimers. It is these dimers that are bound to haptoglobin and can be filtered at the glomerulus.",
"   </p>",
"   <p>",
"    Each subunit in the tetramer is oriented toward the two unlike subunits in different ways (ie,",
"    <span class=\"nowrap\">",
"     alpha1/beta1",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     alpha1/beta2).",
"    </span>",
"    There is stronger binding between alpha1 and beta1 subunits than between alpha1 and beta2 subunits; as a result, dissociation of the oxygenated tetramer into dimers occurs at the",
"    <span class=\"nowrap\">",
"     alpha1/beta2",
"    </span>",
"    interface. During oxygenation and deoxygenation, there is considerable movement along the",
"    <span class=\"nowrap\">",
"     alpha1/beta2",
"    </span>",
"    interface. Hemoglobin mutants with an amino acid substitution at this interface are likely to have markedly abnormal functional properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FUNCTION OF HEMOGLOBIN A",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal physiologic function of hemoglobin is to carry and deliver oxygen to the tissues from the lungs. Another function, delivery of nitric oxide and regulation of vasomotor tone, has been postulated (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Nitric oxide transport'",
"    </a>",
"    below). The oxygenation of hemoglobin as a function of the oxygen concentration is expressed by a sigmoid hemoglobin-oxygen association curve, which has two characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The shape of this curve is due to a phenomenon known as cooperativity whereby partial saturation of hemoglobin with oxygen increases the affinity of the remaining hemes for oxygen (",
"      <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"       figure 2",
"      </a>",
"      ). Heme proteins such as the homotetrameric hemoglobins H (beta4) and Bart's (gamma4) lack the cooperativity of normal tetrameric hemoglobins and have a hyperbolic curve. Myoglobin exists in muscle as a monomer and exhibits no cooperativity.",
"     </li>",
"     <li>",
"      The affinity of hemoglobin for oxygen is characterized by the amount of oxygen bound at any given oxygen concentration. Hemoglobin-oxygen affinity can be modified as discussed below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cooperativity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenomenon of cooperativity is due to the fact that the T form of hemoglobin has a lower affinity for ligands such as oxygen and carbon monoxide (CO) than the R form. The heme-heme interaction, a function of the tetrameric nature of hemoglobin, implies that the four heme groups do not undergo simultaneous oxygenation or deoxygenation; instead, the state of each individual heme with regard to associated oxygen influences the binding of oxygen to the other heme groups.",
"   </p>",
"   <p>",
"    The totally deoxygenated hemoglobin tetramer is slow to bind the first oxygen molecule, but the reaction with oxygen accelerates as oxygenation proceeds. At some point during the sequential addition of oxygen to the four hemes of the molecule, a transition from the T to the R conformation occurs. At this point, the oxygen affinity of the partially liganded molecule increases markedly [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/5\">",
"     5",
"    </a>",
"    ]. When two or three molecules of oxygen are bound, the",
"    <span class=\"nowrap\">",
"     alpha1/beta2",
"    </span>",
"    interface is sufficiently destabilized to flip the quaternary structure from T to R, thereby increasing the affinity of the remaining hemes for oxygen (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Oxygenation and deoxygenation'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In deoxyhemoglobin, the iron atoms lie outside the plane of the porphyrin ring by approximately 0.038 nm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/6\">",
"     6",
"    </a>",
"    ]. The trigger that effects this allosteric transition appears to be the decrease in the atomic radius of heme iron upon the addition of ligand. The smaller iron atom is now able to snap into the plane of the porphyrin ring. This altered heme configuration is amplified by an intramolecular path that transduces this chemical signal to the",
"    <span class=\"nowrap\">",
"     alpha1/beta2",
"    </span>",
"    interface, resulting in increased ligand affinity.",
"   </p>",
"   <p>",
"    Mutagenesis at the distal E7 site has provided insight into other aspects of the molecule, which account for the relative affinity for oxygen versus carbon monoxide (CO) and minimization of the rate of auto-oxidation to nonfunctional methemoglobin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In free heme, the affinity for oxygen is several thousand times lower than that for CO. However, the affinity of hemoglobin for CO is at least 10-fold less than that of free heme. This relative increase in affinity for oxygen is due to the formation of a hydrogen bond with a nitrogen atom on the imidazole of the distal (E7) histidine and the bound oxygen. When an E7 His is replaced with a glycine residue, the affinity for CO increases fourfold [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autooxidation is considerably facilitated by protons. The distal histidine at E7 binds protons, thereby acting as a proton trap and protecting the ferrous heme iron from oxidation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oxygen affinity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen affinity is usually designated by the P50, which is the partial pressure of oxygen at which hemoglobin is 50 percent saturated (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 2",
"    </a>",
"    ). The P50 is normally 27 mmHg at 37&ordm;C and pH 7.4. A shift to the right, with a higher P50, indicates that a larger partial pressure of oxygen is required to saturate hemoglobin (ie, reduced affinity). Oxygen affinity is modulated by pH, CO2, 2,3-BPG and temperature, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oxygen affinity of hemoglobin increases as a function of pH over a range of 6.0 to 8.5, a phenomenon known as the Bohr effect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/9\">",
"     9",
"    </a>",
"    ]. A corollary of this relationship is that deoxyhemoglobin binds protons more strongly than does oxyhemoglobin. Under physiologic conditions, a molecule of hemoglobin releases about 2.8 protons upon oxygenation.",
"   </p>",
"   <p>",
"    A substantial portion of the Bohr effect is due to an intrasubunit salt bond between the positively charged imidazole of beta146 histidine and the negatively charged carboxyl of beta94aspartate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This salt bridge helps to stabilize the deoxy conformation. When hemoglobin is oxygenated, these bonds are broken and protons are released.",
"   </p>",
"   <p>",
"    There are two major physiologic consequences of the Bohr effect. First, oxygen is more easily released at the tissue level due to a higher CO2 and lower pH. Second, oxygen is more easily taken up in the pulmonary circulation where the pH is higher due to the efflux of CO2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Carbamino adducts",
"    </span>",
"    &nbsp;&mdash;&nbsp;CO2 can react with free amino groups at the N termini of the alpha and beta chains to form carbamino complexes. Deoxyhemoglobin forms these complexes more readily than oxyhemoglobin; thus, at any given pH, CO2 lowers oxygen affinity. Normally, about 10 percent of CO2 is transported to the lungs in the form of carbamino hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     2,3-bisphosphoglycerate",
"    </span>",
"    &nbsp;&mdash;&nbsp;2,3 bisphosphoglycerate (2,3-BPG, also called 2,3-diphosphoglycerate or 2,3-DPG) is a potent modulator of the affinity of hemoglobin for oxygen. It is normally present in red cells at a concentration of approximately 5",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    Increasing levels of 2,3-BPG decrease the oxygen affinity, shift the dissociation curve to the right, and increase the delivery of oxygen to tissues. 2,3-BPG is a polyanion which binds strongly to deoxyhemoglobin in a 1:1 molar ratio but weakly to oxyhemoglobin, as described by the following reaction:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Hb.BPG &nbsp;+ &nbsp;4O2 &nbsp;&lt;&mdash;&mdash;&gt; &nbsp; Hb(O2)4 &nbsp;+ &nbsp;BPG",
"   </p>",
"   <p>",
"    Binding takes place in the central cavity between the two beta chains where the negative charges of 2,3-BPG are neutralized by the beta NH2 terminus, betahistidine, beta82 lysine, and beta143 histidine. Binding to deoxyhemoglobin helps to stabilize the T structure and decrease oxygen affinity. In oxyhemoglobin, the H helices of the beta chains are insufficiently spread apart to permit firm binding of 2,3-BPG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen affinity varies inversely with temperature. The decrease in oxygen affinity at elevated body temperature helps to unload oxygen at the tissue at a time when oxygen requirement is likely to be increased.",
"   </p>",
"   <p>",
"    The position and shape of the oxyhemoglobin dissociation curve define the amount of oxygen that is unloaded at the tissue at any given blood flow and hemoglobin concentration. Red cells that are right-shifted have enhanced O2 release when going from a normal arterial pO2 (95 mmHg) to a normal mixed venous pO2 (40 mmHg). This is due to the fact that with this decrease in pO2, a steeper portion of the curve is encompassed. This issue relates to several clinical situations and contributes to the polycythemia associated with hemoglobin mutants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    .) Changes in 2,3-BPG are important in the adaptation to hypoxia and anemia. In acutely hypoxic tissue, the curve is also shifted to the right by the acid environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nitric oxide transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO) is a potent vasodilator. The oxidized nitrosyl derivative of NO can form adducts with proteins, including sulfhydryl groups on cysteine residues. Hemoglobin contains a highly conserved cysteine on the beta subunit, close to the heme pocket: beta93cys. This -SH group has free access to modification when hemoglobin is oxygenated but is sterically blocked when the molecule is deoxygenated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that NO produced in the pulmonary circulation binds to the Cys SH group forming the S-nitrosothiol (SNO) derivative. As blood traverses tissues and unloads oxygen, NO is ejected from hemoglobin and diffuses out of the red blood cell into the lumen of arterioles and capillaries where it serves as a local vasodilating agent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/14-18\">",
"     14-18",
"    </a>",
"    ], and may also serve to control the respiratory drive (",
"    <a class=\"graphic graphic_figure graphicRef70886 \" href=\"UTD.htm?23/62/24549\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link&amp;anchor=H7#H7\">",
"     \"Control of ventilation\", section on 'S-nitrosothiols and the nucleus tractus solitarius'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is some evidence in support of this hypothesis, many more rigorous biochemical and physiologic measurements are required to prove an important role in vivo. It will be difficult to critically assess whether there is oxygen-linked net release of NO from red cells during the rapid transit time from arteries through the precapillary circulation (less than one-half of a second).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STRUCTURE AND FUNCTION OF NORMAL HEMOGLOBINS OTHER THAN HbA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In red cells of adults and in children more than six months of age, HbA",
"    <span class=\"nowrap\">",
"     (alpha2/beta2)",
"    </span>",
"    accounts for about 95 percent of the total hemoglobin. However, other globin genes are preferentially expressed during embryonic and fetal development. For this reason, defects of a particular globin gene have different effects at different developmental stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations of the alpha-globin genes (HBA2, HBA1) are phenotypically apparent early in development and any associated phenotype is likely to persist. Gamma-globin gene (HBG2, HBG1) defects appear in the fetus, can linger into the neonatal period, and if severe, can cause fetal loss.",
"     </li>",
"     <li>",
"      Mutations in the beta-globin gene (HBB), such as those encoding sickle hemoglobin (HbS) or beta thalassemia, become apparent only after the switch from HbF",
"      <span class=\"nowrap\">",
"       (alpha2/gamma2)",
"      </span>",
"      to HbA",
"      <span class=\"nowrap\">",
"       (alpha2/beta2).",
"      </span>",
"      They are compatible with normal fetal survival and may not become apparent until the middle to late months of the first year of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Major clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Beta thalassemia major'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Delta-globin gene (HBD) mutations become detectable late in the first year of life, as this gene is poorly expressed during intrauterine development. Nevertheless, such mutations have no ill effects, as the enfeebled delta gene is expressed at very low levels (3 percent) compared with the beta-globin gene (96 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Embryonic hemoglobins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryonic hemoglobins that contain zeta (HBZ)- or epsilon (HBE1)-globin chains are primarily the product of yolk sac erythroblasts and are detectable only during the very earliest stages of embryogenesis. In early development, between weeks 4 and 14 of gestation, the human embryo synthesizes three distinct hemoglobins. These embryonic hemoglobins are, in their order of formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hb Gower I &mdash;",
"      <span class=\"nowrap\">",
"       zeta2/epsilon2",
"      </span>",
"     </li>",
"     <li>",
"      Hb Portland &mdash;",
"      <span class=\"nowrap\">",
"       zeta2/gamma2",
"      </span>",
"     </li>",
"     <li>",
"      Hb Gower II &mdash;",
"      <span class=\"nowrap\">",
"       alpha2/epsilon2",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By approximately the 14",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation, after establishment of erythropoiesis in the fetal liver and spleen, these embryonic hemoglobins are replaced by HbF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Structure and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryonic hemoglobins, in the absence of any effector (eg, 2,3 BPG, pH, chloride iron) have oxygen affinities and binding rates similar to those of HbA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/20\">",
"     20",
"    </a>",
"    ]. In the presence of organic phosphates, the oxygen affinities of",
"    <span class=\"nowrap\">",
"     zeta2/epsilon2",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     alpha2/epsilon2",
"    </span>",
"    are lowered; in the case of Gower II this occurs to a lesser extent than HbA. This demonstrates that the zeta and epsilon chains do not completely interfere with the binding of 2,3 BPG, but differences with HbA do exist. Hb Portland does not bind phosphates effectively (see below), since its central cavity is formed by gamma chains.",
"   </p>",
"   <p>",
"    Gower II hemoglobin has reduced sensitivity to chloride iron (Cl-). It is indispensable to reduce the destabilizing effect of an excess of positive charges in the central cavity by Cl- binding, in order to preserve the physiological oxygen affinity of hemoglobin. Thus, alterations in Cl- binding are bound to lead to functional alterations. According to crystallographic studies, the tertiary structure of the alpha chain in Hb Gower II is unchanged compared with HbA and HbF [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/21\">",
"     21",
"    </a>",
"    ]. The epsilon chain has a structure very similar to the beta chain, with small differences in the N terminus and the A helix. The Cl- binding sites involve the polar residues within the central cavities.",
"   </p>",
"   <p>",
"    Of all of these residues only one residue is changed (from arg to lys). This change can explain the decrease in Cl- binding only if the pK of lys is low enough for it to be non-ionized under physiological conditions, which is far from certain. There are three other candidate sequence changes within the chain, and a better understanding of the consequence of these changes will require knowledge of the T crystal structure of Hb Gower II. However, it is possible that the decreased Cl- effect is the sum of small aggregated changes, and not the result of a single amino acid substitution.",
"   </p>",
"   <p>",
"    The epsilon-globin chain has a substitution at the beta87 position (from thr to lys) compared with the beta chain. This is reminiscent of the gamma and delta chains, which also have substitutions at this site. Although crystallography does not support a micro-conformational change at this site, this might occur in solution, and would predict that embryonic hemoglobins containing epsilon chains are anti-sickling.",
"   </p>",
"   <p>",
"    Hb Gower II has been probed by using site-directed mutant forms of the protein. Separate mutation of the three amino acids previously identified as candidates for the suppression of chloride sensitivity in the epsilon chain unambiguously identified the beta77 replacement (his&mdash;&gt;asn) in the epsilon chain as the origin of its lower sensitivity towards chloride ions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/22\">",
"     22",
"    </a>",
"    ]. This allows oxygen exchange from the mother to the late embryo under physiological conditions.",
"   </p>",
"   <p>",
"    In Hb Portland, the role of the amino acid at position alpha38 has been also probed using site-directed mutagenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/23\">",
"     23",
"    </a>",
"    ]. When the thr residue at position alpha38, a site universally conserved in all mammals, is changed to a gln, the equilibrium properties of the protein are significantly altered: the R-state is essentially unaffected while the T-state properties are changed. Mutation of the naturally occurring gln38 of the human embryonic hemoglobin zeta chain (the only known non-thr containing globin) to a thr residue shows the converse change in properties produced by the adult mutation, but this is complicated by significant chain heterogeneity in the T state. A molecular model has been described in which a novel interaction between the unusual alpha gln38 and beta tyr145 contribute to the unusual ligand-binding properties of the zeta chain-containing human embryonic hemoglobins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fetal hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the eighth week of gestation, HbF becomes the predominant hemoglobin of the fetus and its levels continue to increase until midway through gestation. The concentration of HbF increases with decreasing gestational age and is regulated developmentally. As an example, the concentration of HbF in an infant born at 28 weeks gestation is approximately 90 percent and decreases to approximately 60 percent at 10 weeks after birth, a value similar to that of full term infant born at 38 weeks (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link&amp;anchor=H8#H8\">",
"     \"Anemia of prematurity\", section on 'Oxygen delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10340141\">",
"    <span class=\"h3\">",
"     Transition from HbF to HbA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transition from HbF to HbA appears to be controlled via a multi-protein complex, which includes expression of BCL11A (B-cell",
"    <span class=\"nowrap\">",
"     lymphoma/leukemia",
"    </span>",
"    11A), a gene which encodes a suppressor of HbF expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] and which is itself likely activated by the transcription factor KLF1 (Kruppel-like factor 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Of interest, hereditary persistence of HbF (HPFH), in which persistent high levels of HbF continue into adulthood, has been attributed in one family to haploinsufficiency for KLF1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/26,29\">",
"     26,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 3.5-kb intergenic region near the 5&rsquo; end of the delta-globin gene appears necessary for gamma-globin silencing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. BCL11A and its partners in this regulatory complex appear to bind to this region in the chromatin of adult erythroid cells. Loss of this region in some patients with thalassemia was associated with an average increase of 2.7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    of HbF, suggesting that silencing of BCL11A or preventing its binding to this site might be of value for increasing HbF levels in patients with thalassemia and sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Structure of the gamma globin chain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-globin genes are duplicated with the 5' HBG2 gene encoding a gly residue at position 136 compared with an ala in the 3' HBG1 gene. As a result, gamma-globin subunits are structurally heterogeneous [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/33\">",
"     33",
"    </a>",
"    ]. (While normal alpha-globin genes are duplicated, their amino acid sequences are identical, although their promoters vary.) The Ggamma and Agamma chains are products of adjacent genes located between the epsilon and delta genes on chromosome 11.",
"   </p>",
"   <p>",
"    The two fetal hemoglobins",
"    <span class=\"nowrap\">",
"     (alpha2/Ggamma2",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     alpha2/Agamma2)",
"    </span>",
"    have similar properties [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/34\">",
"     34",
"    </a>",
"    ]. This striking similarity in protein sequence and gene structure is due to gene duplication and gene conversion, the latter being the non-reciprocal exchange of genetic material between two linked homologous genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One interpretation of this remarkable phenomenon that strives to maintain these two gamma genes to be almost identical, is that there is considerable selective value placed on maintaining the sequence of gamma-globin chains and the structure of HbF. Since HbF is present through most of fetal life, and functionally critical sequence abnormalities could have a major effect on fetal development, maintaining the normal gene sequence is vitally important (see below).",
"   </p>",
"   <p>",
"    Of the 39 amino acid residue differences between gamma- and beta- globin chains, 22 are located on the surface of the molecule. There are four critical substitutions in the",
"    <span class=\"nowrap\">",
"     alpha1/beta1",
"    </span>",
"    area of contact (the packing contact). In HbF this is the strong contact that dissociates only under extreme conditions (high urea concentration, iodine salts, extreme pH). Two of these substitutions, gamma112 thr and gamma130 trp, in the",
"    <span class=\"nowrap\">",
"     alpha1/gamma1",
"    </span>",
"    interface, could be involved in providing the HbF molecule with its resistance to alkali and acid (see below). Sequence differences are not found in the",
"    <span class=\"nowrap\">",
"     alpha1/beta2",
"    </span>",
"    area of contact (sliding contact) that is the center of ligand-dependent conformational changes.",
"   </p>",
"   <p>",
"    Crystallographic studies of HbF at 2.5 &Aring; resolution show almost complete isomorphism between HbA and HbF, with the sole difference being in the N-terminal portion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/36\">",
"     36",
"    </a>",
"    ]. This change, which increases the distance between the 2,3 BPG inserted in the central cavity and the gamma2 his, is possibly a secondary contributor to the reduction in 2,3 BPG effect exhibited by HbF. Another aspect of HbF, not readily understood in terms of mechanism, is its strong globin-heme interaction and lower rate of dimerization compared with HbA (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other changes in Hb F that have been described include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 20 per cent of HbF in the developing fetus has a posttranslational modification in which the N terminus of the gamma chain is acetylated [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/38\">",
"       38",
"      </a>",
"      ]. No other human globin subunits are acetylated, except for mutants that have substitutions of the N-terminal residue [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A common polymorphism occurs only in HBG1, where threonine replaces isoleucine at codon 75 (HbF-Sardinia; HBG1 ile75thr) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/39\">",
"       39",
"      </a>",
"      ]. This polymorphism has an incidence ranging from zero to 40 percent in different populations, leading to further heterogeneity of gamma globins.",
"     </li>",
"     <li>",
"      In the newborn, about two-thirds of the gamma chains have glycine at position 136, while the remaining gamma chains have alanine. This ratio falls during the switch from gamma to beta chain production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Functional properties of hemoglobin F",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb F has several unique properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal red cells have a considerably higher oxygen affinity than do adult red cells because HbF binds 2,3-BPG poorly [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. The low affinity for 2,3-BPG is due to an amino acid substitution, which weakens the binding of 2,3-BPG and leads to stabilization of the molecule in the R (relaxed) state (",
"      <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/42\">",
"       42",
"      </a>",
"      ]. Physiologically, this property ensures that the hemoglobin of the fetus is oxygenated at the expense of maternal HbA, thereby facilitating the transport of oxygen across the placenta.",
"     </li>",
"     <li>",
"      Hb F is a much more stable hemoglobin tetramer than HbA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/43\">",
"       43",
"      </a>",
"      ]. It dissociates into dimers less readily than HbA, is resistant to losing hemes, and is remarkably resistant to denaturation at extremes of pH. This latter property (ie, alkali-resistant hemoglobin) has proved to be a very useful, although indirect, method for estimating the content of HbF within a hemolysate.",
"     </li>",
"     <li>",
"      The red cells of the newborn contain about 80 percent HbF and 20 percent HbA. By the time individuals are older than six months, HbF constitutes less than 1 percent of the total hemoglobin, and is distributed",
"      <strong>",
"       unevenly",
"      </strong>",
"      among red cells [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/44\">",
"       44",
"      </a>",
"      ]. In normal subjects, only 0.1 to 7 percent of red cells contain detectable amounts of HbF [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/45\">",
"       45",
"      </a>",
"      ]. These \"F cells\" contain approximately 5 pg of HbF, or approximately 20 percent of the total hemoglobin within the cell. The number of F cells appears to be genetically determined in normal kindreds [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HbF is increased to a variable extent in several hereditary disorders and some hematologic malignancies. These include beta thalassemia, hereditary persistence of fetal hemoglobin, sickle cell anemia, and congenital aplastic anemia.",
"     </li>",
"     <li>",
"      Increasing the concentration of HbF within the red cells of patients with sickle cell disease reduces the polymerization tendency of deoxy sickle hemoglobin (HbS). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H3#H3\">",
"       \"Specific therapies for sickle cell disease\", section on 'Reactivating fetal hemoglobin synthesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HEMOGLOBIN A2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 2.5 percent of the hemoglobin in normal red cells is HbA2",
"    <span class=\"nowrap\">",
"     (alpha2/delta2).",
"    </span>",
"    It can be readily separated from Hb A by electrophoresis or ion-exchange chromatography. This minor hemoglobin component is evenly distributed among red cells, and its functional behavior is very similar to that of HbA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/12\">",
"     12",
"    </a>",
"    ]. The delta- and beta-globin chains have identical sequence in all but 10 of 146 residues.",
"   </p>",
"   <p>",
"    HbA2 is present in humans, apes, and New World monkeys, but not in Old World monkeys, where the delta-globin gene has accumulated inactivating mutations and has become a pseudogene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/46\">",
"     46",
"    </a>",
"    ]. It is expressed in these human ancestors in low levels, except for the Galago, which has an exceptionally altered delta gene sequence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative instability of delta globin mRNA was originally postulated to be responsible for the premature decline in delta-globin synthesis. The half life of delta globin mRNA is less than one third that of beta-globin mRNA, probably due to changes in the delta mRNA sequence in the 3' untranslated region. However, this mechanism alone does not account for the vastly reduced concentration of HbA2 compared with HbA. HbA and HbA2 have almost identical molecular stability, making it unlikely that differential post-translational survival of the two molecules accounts for this difference [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/47\">",
"     47",
"    </a>",
"    ]. Similarly, mutations in the delta-globin gene promoter do not explain totally the reduced accumulation of delta-globin mRNA. Additional sites in the delta-globin gene may account for its reduced expression.",
"   </p>",
"   <p>",
"    A genome-wide association study in normal Northern Europeans found that 42 percent of the common inter-individual variability in HbA2 levels was governed by genetic factors, with little influence of age or sex. Two implicated loci were the HBS1L-MYB locus on chromosome 6q, which has been shown to have pleiotropic effects on other hematologic traits and to be associated with HbF levels, and a second locus on chromosome 11p surrounding HBB, the gene encoding beta-globin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative rate of synthesis of this minor hemoglobin component is markedly curtailed in the final stages of erythroid development [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The level of HbA2 appears to depend on the rate of assembly of hemoglobin subunits that, in turn, depends on the charge of its subunits. The delta-globin chain is more positively charged than the beta-globin chain and therefore has reduced affinity for the positively charged alpha-globin chain, and is altered in a number of congenital and acquired diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/47,51\">",
"     47,51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal levels of HbA2 are 2.8 &plusmn; 0.2 percent (range: 2.1 to 3.1)",
"     </li>",
"     <li>",
"      The percent of HbA2 is increased in beta thalassemia trait (5.4 &plusmn; 0.4 percent, range: 4.5 to 6.2), a finding that is a useful diagnostic aid. HbA2 is also slightly increased in megaloblastic anemia.",
"     </li>",
"     <li>",
"      HbA2 levels in the borderline high range may have mutations in the",
"      <em>",
"       KLF1",
"      </em>",
"      gene (3.5 &plusmn; 0.2, range: 3.1 to 4.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HbA2 is decreased in alpha-thalassemia, iron deficiency, and sideroblastic anemias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Function",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbA2 has functional properties that are nearly identical to those of HbA. It has slightly higher oxygen affinity than HbA, while the Bohr effect, cooperativity, and response to 2,3 BPG are identical [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/52\">",
"     52",
"    </a>",
"    ]. Thermal stability of HbA2 is greater than that of HbA, which may be due to the delta116 arg that can form a salt bridge with alpha114 pro, increasing even further the stability of the",
"    <span class=\"nowrap\">",
"     alpha1/beta1",
"    </span>",
"    packing contact. HbA2 has slightly increased susceptibility to autoxidation to methemoglobin and its hemichrome has increased stability. These differences, along with a charge difference [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/53\">",
"     53",
"    </a>",
"    ], were suggested as explanations for the increased membrane binding of this molecule. Like HbF, HbA2 inhibits the polymerization of HbS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The positive charge of HbA2 may endow it with properties similar to other positively charged hemoglobins like HbC (HBB glu6lys) relative to its interaction with the erythrocyte membrane, possibly at the level of the cytosolic portion of the Cl- channel (Band 3). Since highly positively charged hemoglobins like HbC may damage the erythrocyte membrane, the effects of very high levels of HbA2 could also be deleterious.",
"   </p>",
"   <p>",
"    The presence of a variant HbA2 at polymorphic frequencies in the Dogon region of Mali hints at a selective advantage for this variant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     GLYCATED HEMOGLOBINS (HEMOGLOBIN A1C)",
"    </span>",
"    &nbsp;&mdash;&nbsp;When hemoglobin from normal adult red cells is analyzed by column chromatography, several minor components can be detected that have lower isoelectric points than HbA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. These are designated A1a1, A1a2, A1b and A1c. Hemoglobin A1c accounts for approximately 3 percent of the hemoglobin in normal adult red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/58\">",
"     58",
"    </a>",
"    ]. This minor component differs from HbA only at the N-terminal amino group of each beta chain, in which glucose is attached nonenzymatically by a ketoamine linkage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In addition, approximately 5 percent of hemoglobin molecules have glucose linked to certain lysine residues. These adducts cannot be separated from unmodified hemoglobins by ordinary chromatography or electrophoresis, but can be isolated by means of an affinity resin containing phenylboronate, which binds to sugar hydroxyl groups.",
"   </p>",
"   <p>",
"    Patients with diabetes mellitus may have levels of HbA1c that are two to three times higher than normal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/61\">",
"     61",
"    </a>",
"    ]. Furthermore, measurement of HbA1c has proved to be a useful independent assessment of the degree of diabetic control. Glucose becomes irreversibly attached to hemoglobin during the life of the red cell at a rate dependent upon the prevailing blood glucose. Several million red cells are destroyed every day, while an equal number of new ones are formed. Thus, the average amount of glycated hemoglobin changes in a dynamic way and reflects the mean blood glucose over the previous six to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link&amp;anchor=H2#H2\">",
"     \"Estimation of blood glucose control in diabetes mellitus\", section on 'Estimation of mean blood glucose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HbA1c is also a prototype for the glycosylation of other proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/63\">",
"     63",
"    </a>",
"    ]. Over a period of weeks to months, glycated proteins can undergo further rearrangement reactions to form fluorescent advanced glycation end products. These compounds may contribute importantly to the long-term complications of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a similar manner, sugar phosphates and other red cell metabolites combine with hemoglobin at the beta-N terminus to form less abundant adducts. HbA1b is an adduct of pyruvate with the beta-N terminus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/65\">",
"     65",
"    </a>",
"    ]. These hemoglobins are formed slowly and continuously throughout the 120-day life span of the red cell. Consequently, individuals who have increased red cell turnover (hemolysis) have decreased levels of these minor hemoglobin components. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link&amp;anchor=H5#H5\">",
"     \"Estimation of blood glucose control in diabetes mellitus\", section on 'Sources of error'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER POST-TRANSLATIONAL MODIFICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although glucose adducts are by far the most common and abundant type of chemical modification of hemoglobin, other small molecules are also capable of forming covalent linkages that may reflect significant metabolic perturbations. Examples include cyanate adducts in uremic patients, acetaldehyde adducts in alcoholics, and porphyrin-substituted hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23001/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the newborn and adult, hemoglobin is a tetrameric protein consisting of two pairs of globin polypeptide chains: one pair of alpha-globin chains, and one pair of non-alpha-globin chains (ie, beta-, gamma-, or delta-globin). There is no substitute for alpha globin in the formation of any of the normal hemoglobins following birth. Thus, absence any alpha-globin is generally incompatible with extrauterine life. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Structure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hemoglobin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;In red cells of adults, and in children more than six months of age, HbA",
"    <span class=\"nowrap\">",
"     (alpha2/beta2)",
"    </span>",
"    accounts for about 95 percent of the total hemoglobin. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Function of hemoglobin A'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hemoglobin F",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb F (alpha",
"    <span class=\"nowrap\">",
"     2/gamma2)",
"    </span>",
"    is the main hemoglobin during late fetal life. The concentration of HbF in a full-term infant is approximately 60 percent, decreasing to about 1 to 2 percent in the adult. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Fetal hemoglobin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hemoglobin A2",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbA2",
"    <span class=\"nowrap\">",
"     (alpha2/delta2)",
"    </span>",
"    is a minor hemoglobin throughout fetal and adult life. Its concentration in the adult is approximately 2.5 percent. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Hemoglobin A2'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hemoglobin A1c",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb A1c differs from Hb A only in the addition of glucose molecules. It accounts for approximately 3 percent of the hemoglobin in normal adult red cells and about twice this level in patients with diabetes mellitus. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Glycated hemoglobins (hemoglobin A1c)'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/1\">",
"      PAULING L, ITANO HA. Sickle cell anemia a molecular disease. Science 1949; 110:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/2\">",
"      Schechter AN. Hemoglobin research and the origins of molecular medicine. Blood 2008; 112:3927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/3\">",
"      Hardison R. Hemoglobins from bacteria to man: evolution of different patterns of gene expression. J Exp Biol 1998; 201:1099.",
"     </a>",
"    </li>",
"    <li>",
"     Perutz MF. Molecular anatomy, physiology, and pathology of hemoglobin. In: The Molecular Basis of Blood Disorders, Stamatoyannopoulos G, Nienhuis AW, et al. (Eds), WB Saunders, Philadelphia 1987. p.127.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/5\">",
"      MONOD J, WYMAN J, CHANGEUX JP. ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. J Mol Biol 1965; 12:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/6\">",
"      Fermi G, Perutz MF, Shulman RG. Iron distances in hemoglobin: comparison of x-ray crystallographic and extended x-ray absorption fine structure studies. Proc Natl Acad Sci U S A 1987; 84:6167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/7\">",
"      Nagai K, Perutz MF, Poyart C. Studies of haemoglobin functions by site-directed mutagenesis. Philos Trans R Soc Lond [A] 1986; 317:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/8\">",
"      Perutz MF. Mechanisms regulating the reactions of human hemoglobin with oxygen and carbon monoxide. Annu Rev Physiol 1990; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/9\">",
"      Bohr C, Hasselbalch K, Krogh A. Ueber einen in biologischer Beziehung wichtigen Einfluss. den die Kohlen- sauerespannung des Blutes auf dessen Sauerstoffbinding ubt. Skand Arch Physiol 1904; 16:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/10\">",
"      Riggs AF. The Bohr effect. Annu Rev Physiol 1988; 50:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/11\">",
"      Busch MR, Mace JE, Ho NT, Ho C. Roles of the beta 146 histidyl residue in the molecular basis of the Bohr effect of hemoglobin: a proton nuclear magnetic resonance study. Biochemistry 1991; 30:1865.",
"     </a>",
"    </li>",
"    <li>",
"     Bunn HF, Forget BG. Hemoglobin: Molecular, Genetic and Clinical Aspects, WB Saunders, Philadelphia 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/13\">",
"      Pawloski JR, Stamler JS. Nitric oxide in RBCs. Transfusion 2002; 42:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/14\">",
"      Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996; 380:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/15\">",
"      Stamler JS, Jia L, Eu JP, et al. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 1997; 276:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/16\">",
"      Gow AJ, Stamler JS. Reactions between nitric oxide and haemoglobin under physiological conditions. Nature 1998; 391:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/17\">",
"      Crawford JH, Isbell TS, Huang Z, et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006; 107:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/18\">",
"      Gladwin MT, Kim-Shapiro DB. The functional nitrite reductase activity of the heme-globins. Blood 2008; 112:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/19\">",
"      Hofmann O, Mould R, Brittain T. Allosteric modulation of oxygen binding to the three human embryonic haemoglobins. Biochem J 1995; 306 ( Pt 2):367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/20\">",
"      Hofmann OM, Brittain T. Partitioning of oxygen and carbon monoxide in the three human embryonic hemoglobins. Hemoglobin 1998; 22:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/21\">",
"      Sutherland-Smith AJ, Baker HM, Hofmann OM, et al. Crystal structure of a human embryonic haemoglobin: the carbonmonoxy form of gower II (alpha2 epsilon2) haemoglobin at 2.9 A resolution. J Mol Biol 1998; 280:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/22\">",
"      Zheng T, Zhu Q, Brittain T. Origin of the suppression of chloride ion sensitivity in human embryonic hemoglobin Gower II. IUBMB Life 1999; 48:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/23\">",
"      Zheng T, Brittain T, Watmough NJ, Weber RE. The role of amino acid alpha38 in the control of oxygen binding to human adult and embryonic haemoglobin Portland. Biochem J 1999; 343 Pt 3:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/24\">",
"      Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008; 322:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/25\">",
"      Sankaran VG, Xu J, Orkin SH. Advances in the understanding of haemoglobin switching. Br J Haematol 2010; 149:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/26\">",
"      Zhou D, Liu K, Sun CW, et al. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010; 42:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/27\">",
"      Sankaran VG, Nathan DG. Reversing the hemoglobin switch. N Engl J Med 2010; 363:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/28\">",
"      Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 2011; 117:3945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/29\">",
"      Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010; 42:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/30\">",
"      Sankaran VG, Xu J, Byron R, et al. A functional element necessary for fetal hemoglobin silencing. N Engl J Med 2011; 365:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/31\">",
"      Forget BG. Progress in understanding the hemoglobin switch. N Engl J Med 2011; 365:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/32\">",
"      Ghedira ES, Lecerf L, Faubert E, et al. Estimation of the difference in HbF expression due to loss of the 5' &delta;-globin BCL11A binding region. Haematologica 2013; 98:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/33\">",
"      Huisman TH, Schroeder WA, Bannister WH, Grech JL. Evidence for four nonallelic structural genes for the chain of human fetal hemoglobin. Biochem Genet 1972; 7:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/34\">",
"      Adachi K, Kim J, Asakura T, Schwartz E. Characterization of two types of fetal hemoglobin: alpha 2G gamma 2 and alpha 2A gamma 2. Blood 1990; 75:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/35\">",
"      Slightom JL, Blechl AE, Smithies O. Human fetal G gamma- and A gamma-globin genes: complete nucleotide sequences suggest that DNA can be exchanged between these duplicated genes. Cell 1980; 21:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/36\">",
"      Frier JA, Perutz MF. Structure of human foetal deoxyhaemoglobin. J Mol Biol 1977; 112:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/37\">",
"      Bunn HF. Subunit assembly of hemoglobin: an important determinant of hematologic phenotype. Blood 1987; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/38\">",
"      SCHROEDER WA, CUA JT, MATSUDA G, FENNINGER WD. Hemoglobin F1, an acetyl-containing hemoglobin. Biochim Biophys Acta 1962; 63:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/39\">",
"      Ricco G, Mazza U, Turi RM, et al. Significance of a new type of human fetal hemoglobin carrying a replacement isoleucine replaced by threonine at position 75 )E 19) of the gamma chain. Hum Genet 1976; 32:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/40\">",
"      Miwa I, Erd&ouml;s EG, Seki T. Presence of three peptides in urinary kinin (substance Z) preparations. Life Sci 1968; 7:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/41\">",
"      Tyuma I, Shimizu K. Different response to organic phosphates of human fetal and adult hemoglobins. Arch Biochem Biophys 1969; 129:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/42\">",
"      Adachi K, Konitzer P, Pang J, et al. Amino acids responsible for decreased 2,3-biphosphoglycerate binding to fetal hemoglobin. Blood 1997; 90:2916.",
"     </a>",
"    </li>",
"    <li>",
"     Nagel RL, Steinberg MH. of the embryo and fetus and minor hemoglobins of adults. In: Disorders of Hemoglobin: Genetics, pathophysiology, clinical management, Steinberg MH, Forget BG, Higgs DR, et al. (Eds), Cambridge University Press, Cambridge 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/44\">",
"      Boyer SH, Belding TK, Margolet L, Noyes AN. Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. Science 1975; 188:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/45\">",
"      Wood WG, Stamatoyannopoulos G, Lim G, Nute PE. F-cells in the adult: normal values and levels in individuals with hereditary and acquired elevations of Hb F. Blood 1975; 46:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/46\">",
"      Martin SL, Vincent KA, Wilson AC. Rise and fall of the delta globin gene. J Mol Biol 1983; 164:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/47\">",
"      Steinberg MH, Adams JG 3rd. Hemoglobin A2: origin, evolution, and aftermath. Blood 1991; 78:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/48\">",
"      Menzel S, Garner C, Rooks H, et al. HbA2 levels in normal adults are influenced by two distinct genetic mechanisms. Br J Haematol 2013; 160:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/49\">",
"      RIEDER RF, WEATHERALL DJ. STUDIES ON HEMOGLOBIN BIOSYNTHESIS: ASYNCHRONOUS SYNTHESIS OF HEMOGLOBIN A AND HEMOGLOBIN A2 BY ERYTHROCYTE PRECURSORS. J Clin Invest 1965; 44:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/50\">",
"      Roberts AV, Weatherall DJ, Clegg JB. The synthesis of human haemoglobin A 2 during erythroid maturation. Biochem Biophys Res Commun 1972; 47:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/51\">",
"      Perseu L, Satta S, Moi P, et al. KLF1 gene mutations cause borderline HbA(2). Blood 2011; 118:4454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/52\">",
"      Bunn HF, Briehl RW. The interaction of 2,3-diphosphoglycerate with various human hemoglobins. J Clin Invest 1970; 49:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/53\">",
"      Ranney HM, Lam R, Rosenberg G. Some properties of hemoglobin A2. Am J Hematol 1993; 42:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/54\">",
"      Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A 1979; 76:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/55\">",
"      Ducrocq R, Bennani M, Bellis G, et al. Hemoglobinopathies in the Dogon Country: presence of beta S, beta C, and delta A' genes. Am J Hematol 1994; 46:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/56\">",
"      Allen DW, Schroeder WA, Balog J. Observations on the chromatographic heterogeneity of normal adult and fetal human hemoglobins. J Am Chem Soc 1958; 80:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/57\">",
"      McDonald MJ, Shapiro R, Bleichman M, et al. Glycosylated minor components of human adult hemoglobin. Purification, identification, and partial structural analysis. J Biol Chem 1978; 253:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/58\">",
"      Garlick RL, Mazer JS, Higgins PJ, Bunn HF. Characterization of glycosylated hemoglobins. Relevance to monitoring of diabetic control and analysis of other proteins. J Clin Invest 1983; 71:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/59\">",
"      Bookchin RM, Gallop PM. Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group. Biochem Biophys Res Commun 1968; 32:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/60\">",
"      Bunn HF, Haney DN, Gabbay KH, Gallop PM. Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c. Biochem Biophys Res Commun 1975; 67:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/61\">",
"      Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978; 200:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/62\">",
"      Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/63\">",
"      Makita Z, Vlassara H, Rayfield E, et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992; 258:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/64\">",
"      Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/65\">",
"      Prome D, Blouquit Y, Ponthus C, et al. Structure of the human adult hemoglobin minor fraction A1b by electrospray and secondary ion mass spectrometry. Pyruvic acid as amino-terminal blocking group. J Biol Chem 1991; 266:13050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/66\">",
"      Fl&uuml;ckiger R, Harmon W, Meier W, et al. Hemoglobin carbamylation in uremia. N Engl J Med 1981; 304:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/67\">",
"      Stevens VJ, Fantl WJ, Newman CB, et al. Acetaldehyde adducts with hemoglobin. J Clin Invest 1981; 67:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23001/abstract/68\">",
"      Hoberman HD. Post-translational modification of hemoglobin in alcoholism. Biochem Biophys Res Commun 1983; 113:1004.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7072 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_23001=[""].join("\n");
var outline_f22_29_23001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oxygenation and deoxygenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FUNCTION OF HEMOGLOBIN A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cooperativity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - pH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Carbamino adducts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - 2,3-bisphosphoglycerate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Temperature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nitric oxide transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STRUCTURE AND FUNCTION OF NORMAL HEMOGLOBINS OTHER THAN HbA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Embryonic hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Structure and function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fetal hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10340141\">",
"      - Transition from HbF to HbA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Structure of the gamma globin chain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Functional properties of hemoglobin F",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HEMOGLOBIN A2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      GLYCATED HEMOGLOBINS (HEMOGLOBIN A1C)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER POST-TRANSLATIONAL MODIFICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hemoglobin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hemoglobin F",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hemoglobin A2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hemoglobin A1c",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7072|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/32/6656\" title=\"figure 1\">",
"      Alpha and beta globin gene clusters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 2\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/62/24549\" title=\"figure 3\">",
"      Ventilatory effects of SNOs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=related_link\">",
"      Genetic disorders of hemoglobin oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=related_link\">",
"      Unstable hemoglobin variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_29_23002="MRI of the breast and emerging technologies";
var content_f22_29_23002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   MRI of the breast and emerging technologies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23002/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23002/contributors\">",
"     Priscilla J Slanetz, MD, MPH, FACR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23002/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23002/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23002/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/29/23002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/29/23002/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/29/23002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1930667\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) of the breast is an important tool for the detection of breast cancer (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86202 \" href=\"UTD.htm?38/13/39126\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86203 \" href=\"UTD.htm?18/24/18819\">",
"     image 2",
"    </a>",
"    ) and assessment of silicone implant integrity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58055 \" href=\"UTD.htm?25/18/25888\">",
"     image 3",
"    </a>",
"    ). The use of MRI with contrast agents for the detection of breast cancer was first reported in 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/1\">",
"     1",
"    </a>",
"    ]. The high sensitivity of MRI for breast cancer has led to the increasing use of MRI for breast cancer detection, assessment, and treatment monitoring, although appropriate indications, scanning technique, and interpretation remain variable among facilities.",
"   </p>",
"   <p>",
"    This topic will review breast MRI technique, interpretation, and indications as well as emerging tools for breast cancer detection. Issues regarding screening for breast cancer, the role of mammography and ultrasound in women with suspected disease, surveillance for patients with known breast cancer, and the physics of MRI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link\">",
"     \"Principles of magnetic resonance imaging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=see_link&amp;anchor=H12559900#H12559900\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606309\">",
"    <span class=\"h1\">",
"     BREAST MRI TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) creates images of the breast by measuring changes in the movement of protons in fat and water with the application of changing magnetic fields. By utilizing the differences in tissue relaxation characteristics, an image is acquired by processing the signal changes that occur following application of pulses of energy. The physics of MRI is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link&amp;anchor=H2#H2\">",
"     \"Principles of magnetic resonance imaging\", section on 'MR physics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast MRI for the detection of breast cancer requires administration of the contrast agent gadolinium. The use of MRI for breast cancer detection is based on the concept of tumor angiogenesis or neovascularity. Tumor associated blood vessels have increased permeability, which leads to prompt take up and release of gadolinium within the first one to two minutes after administration, leading to a pattern of rapid enhancement and washout on MRI (",
"    <a class=\"graphic graphic_figure graphicRef74017 \" href=\"UTD.htm?24/2/24613\">",
"     figure 1",
"    </a>",
"    ). This dynamic rapid enhancement pattern helps to distinguish breast cancers from benign lesions. Breast MRI techniques continue to evolve, but some general recommendations can be made based on minimum standards used by the American College of Radiology Imaging Network (ACRIN) 6667 Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/2\">",
"     2",
"    </a>",
"    ] and the European Society of Breast Imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bilateral breast examination",
"      </strong>",
"      ��� Both breasts should be evaluated in an MRI study, for comparison purposes, even when concern about possible pathology involves only one breast.",
"     </li>",
"     <li>",
"      <strong>",
"       Magnet",
"      </strong>",
"      ��� The magnet field strength recommended for breast MRI is &ge;1.5-Tesla. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Coil ���",
"      </strong>",
"      A dedicated breast coil should be used for breast MRI. The breast coil is designed to receive signals generated from breast tissue and permits imaging of both breasts simultaneously. Surface coils are necessary to achieve adequate spatial resolution while maintaining high signal-to-noise levels.",
"     </li>",
"     <li>",
"      <strong>",
"       Positioning ���",
"      </strong>",
"      Patients are placed in the prone position, over the breast coil, which has openings for the patient&rsquo;s breasts. The coils surround the breasts and detect the magnetic signals from the breast. Some centers image the patient with the breasts in mild compression, which minimizes motion artifact and aids in biopsy planning.",
"     </li>",
"     <li>",
"      <strong>",
"       Patient comfort",
"      </strong>",
"      ��� Patients are given ear plugs before the exam begins to help diminish the loud &ldquo;knocking&rdquo; sounds that are typically heard during an MRI exam. Claustrophobia can be diminished with a short-acting anxiolytic prior to the exam.",
"     </li>",
"     <li>",
"      <strong>",
"       Contrast ���",
"      </strong>",
"      Intravenous gadolinium contrast must be used to maximize cancer detection and is administered before breast MRI to highlight the neovascularity associated with cancers. Contrast is",
"      <strong>",
"       not",
"      </strong>",
"      necessary when the study is performed to evaluate silicone implant integrity.",
"      <br/>",
"      <br/>",
"      Allergic and anaphylactoid reactions to gadolinium are rare, but can occur. In addition, in patients with renal failure, gadolinium can cause contrast nephropathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nephrogenic systemic fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link&amp;anchor=H39#H39\">",
"       \"Principles of magnetic resonance imaging\", section on 'MR contrast agents and renal failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Imaging ���",
"      </strong>",
"      Images are acquired within 45 seconds of contrast injection and then every one to two minutes with completion within four minutes in order to observe the early preferential signal enhancement associated with the hypervascularity of malignant tumors. Slice thickness should be &le;3 mm.",
"      <br/>",
"      <br/>",
"      After the first few minutes following contrast injection, benign breast tissue may also enhance. This time constraint means that a compromise must be reached between temporal and spatial resolution. Imaging strategies such as high spatial resolution and the use of fat-suppression techniques improve the sensitivity of breast MRI for small or multifocal lesions, but also increase scan times [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Dynamic techniques, in which images are acquired at intervals of one minute or less, achieve higher temporal resolution and improve specificity by allowing the time course of contrast uptake to be better defined [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. Alternative approaches combine low temporal resolution kinetic information with high spatial resolution anatomic information as a means of achieving high sensitivity and specificity in a single-scan technique [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/9-12\">",
"       9-12",
"      </a>",
"      ]. Most centers compromise by acquiring temporal resolution at 1 to 1 minute 30 seconds with higher spatial resolution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1930682\">",
"    <span class=\"h1\">",
"     MRI INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast MRI images are analyzed for morphology and initial and delayed contrast enhancement. Lesions are categorized as mass or non-mass lesions. The sensitivity of breast MRI is reported as 71 to 100 percent; however, the specificity is less than 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The low specificity is due to the overlap in the enhancement pattern of benign and malignant lesions. Positive findings are more likely to be accurate for mass lesions than non-mass lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/15\">",
"     15",
"    </a>",
"    ]. Breast MRI findings must be correlated with the patient&rsquo;s mammographic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sonographic imaging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mass lesions are assessed for shape, margin characteristics, and enhancement patterns. Margin characteristics, such as smooth, irregular, or spiculated margins, are significant predictors of malignant versus benign diagnoses. As with mammography, masses with irregular or spiculated margins are worrisome for malignancy. Rapid uptake and washout of gadolinium is seen more commonly in malignant lesions. Progressive enhancement over time is most often encountered in benign lesions or normal breast tissue. In one study of 266 lesions detected on breast MRI, progressive enhancement was seen with 83 percent of the benign lesions as compared with 9 percent of the malignant lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Non-mass lesions are characterized by spatial distribution and patterns of enhancement within the breast. Spatial distribution can be ductal or segmental. A stippled enhancement pattern is a significant predictor of malignant versus benign diagnoses. The non-mass lesions present significant diagnostic challenges and account for a high percentage of false positives. As an example, in one study of 132 patients who underwent 151 biopsies for breast lesions detected on breast MRI, non-mass lesions represented only 20 percent of all lesions detected, but accounted for almost half of the false positive interpretations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6635177\">",
"    <span class=\"h2\">",
"     MRI of high-risk breast lesions identified by core biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast MRI is sometimes used as an adjunct to further assess high-risk proliferative breast lesions with or without atypia, including papillomas, radial sclerosing lesions, lobular neoplasias, and atypical hyperplasias, identified by core needle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In a retrospective review of MRI assessment of 227 high-risk breast lesions, contrast enhancing lesions (n=155) were significantly more likely to be associated with a breast malignancy (invasive or noninvasive) compared with nonenhancing lesions (18 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/19\">",
"     19",
"    </a>",
"    ]. Diagnosis was confirmed by an excision of the lesion. Cancer probability was also greater for non-mass lesions compared with mass lesions (43 versus 14 percent).",
"   </p>",
"   <p>",
"    However, the negative predictive value (NPV) is low for proliferative lesions with atypia, including lobular neoplasias (NPV 88 percent) and atypical ductal hyperplasia (NPV 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/18\">",
"     18",
"    </a>",
"    ]. These lesions should be excised when identified on a core needle biopsy. In comparison, the NPV for proliferative lesions without atypia (papilloma and radial scar) was 97.4 and 97.6 percent, respectively. Patients with these lesions may be safely observed with repeat annual mammographic, ultrasound or MRI imaging, depending upon patient and clinician preference.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of benign breast disease\", section on 'Proliferative breast lesions without atypia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of benign breast disease\", section on 'Atypical hyperplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536410\">",
"    <span class=\"h2\">",
"     Quality control considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal changes and cancer treatments can affect the accuracy of breast MRIs and should be taken into account when scheduling and interpreting the study. Although there is variation in the performance of breast MRIs, reporting should follow standard guidelines. Facilities that perform breast MRI should have MRI-biopsy capability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Menstrual cycle &ndash;",
"      </strong>",
"      To minimize the effects of physiologic glandular enhancement that accompany the menstrual cycle, premenopausal patients or patients on cyclic hormone replacement therapy should be imaged between days 7 to 14 of their cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"       \"Physiology of the normal menstrual cycle\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lactation",
"      </strong>",
"      &minus; Breast MRI during lactation is of limited value given the increased breast density and rapid diffuse enhancement that occur as a result of normal hormonal changes and interfere with accurate interpretation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=see_link\">",
"       \"Physiology of lactation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cancer treatment &minus;",
"      </strong>",
"      Surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy within 12 to 18 months before breast MRI can lead to increased gadolinium uptake and false positive studies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. It is not known how recent chemotherapy impacts gadolinium uptake, although there are reports that selective estrogen receptor modulators (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ) and aromatase inhibitors (eg, Arimidex) can cause malignancies to appear smaller or even undetectable on mammography [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       MRI reporting",
"      </strong>",
"      &mdash; Breast MRIs are increasingly reported using the Breast Imaging Reporting and Data System (BI-RADS) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/30\">",
"       30",
"      </a>",
"      ]. The BI-RADS system was originally developed by the American College of Radiology to standardize mammography reporting, but is now also used for breast ultrasound and MRI (",
"      <a class=\"graphic graphic_table graphicRef66601 \" href=\"UTD.htm?38/19/39227\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/31\">",
"       31",
"      </a>",
"      ]. However, the probability of malignancy for these assessment codes for ultrasound and MRI has not been established, although it is believed that they are likely similar to that with mammography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H15#H15\">",
"       \"Breast imaging: Mammography and ultrasonography\", section on 'The BI-RADS categories'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Standardization ���",
"      </strong>",
"      The specific sequences acquired during the examination vary between facilities [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/32\">",
"       32",
"      </a>",
"      ]. In addition, the dynamic enhancement data often are not archived with the image files. The lack of standardization in breast MRI impairs the ability to compare studies from different institutions, thus leading to repeat MRIs when patients seek second opinions.",
"     </li>",
"     <li>",
"      <strong>",
"       Biopsy capability ���",
"      </strong>",
"      Based on current National Comprehensive Cancer Network (NCCN) guidelines, imaging centers that perform MRI should have the ability to perform MRI guided needle sampling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wire localization of MRI detected findings [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/33\">",
"       33",
"      </a>",
"      ]. Almost half of abnormal findings on MRI may not be evident on other imaging studies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H11#H11\">",
"       \"Breast biopsy\", section on 'MRI-guided breast biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cost ���",
"      </strong>",
"      In the United States, MRI of the breast is expensive, costing approximately 10 to 15 times more than mammography or ultrasound, and is not uniformly reimbursed by insurance. In addition, for 10 to 30 percent of all women who undergo MRI, the study results in recommendation for follow up MRI in six months to reassess nonspecific, but probably benign findings. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3948722\">",
"    <span class=\"h1\">",
"     PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications for breast MRI include pregnancy, implanted devices and foreign bodies, and any prior history of gadolinium allergy or diminished renal function. Since no guideline can cover all devices, when the safety of particular devices is being considered, readers are referred to safety information for specific devices which is compiled on dedicated web sites (",
"    <a class=\"external\" href=\"file://www.mrisafety.com/\">",
"     www.MRIsafety.com",
"    </a>",
"    ) and, when available, manufacturer's product information [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The contraindications for MRI are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link&amp;anchor=H19#H19\">",
"     \"Principles of magnetic resonance imaging\", section on 'Precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633667\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR BREAST MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate use of breast MRI is established for certain indications, while others are still being investigated. Breast MRI has been used for the assessment of silicone implant integrity, diagnosis of occult primary breast cancers, determination of disease extent in newly diagnosed breast cancer patients, documentation of response to neoadjuvant chemotherapy, diagnosis of recurrence, clarification of inconclusive clinical or mammographic findings, and screening of high risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633682\">",
"    <span class=\"h2\">",
"     Assessment of breast implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast MRI is useful for detection of silicone implant rupture and diagnosis of masses caused by free silicone injection. There is no role for breast MRI in saline implant assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633704\">",
"    <span class=\"h3\">",
"     Silicone implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most silicone implants have a shell around the actual implant capsule; hence implant ruptures are described as intracapsular or extracapsular [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/37\">",
"     37",
"    </a>",
"    ]. Intracapsular ruptures are defined as rupture of the silicone shell or envelope around the liquid silicone, with an intact fibrous capsule. Extracapsular ruptures are defined as rupture of both the envelope and fibrous capsule, allowing leakage into surrounding tissue. Both types of rupture usually require surgical removal of the implant. Surgical excision and replacement of an extracapsular rupture is technically more challenging because of the silicone leakage into surrounding tissue.",
"   </p>",
"   <p>",
"    Breast MRI is the most useful imaging test for detecting both intracapsular and extracapsular ruptures of a silicone breast implant with a sensitivity and specificity of over 90 percent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53026 \" href=\"UTD.htm?28/39/29298\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. The most reliable sign of rupture on MRI is the presence of multiple curvilinear lines, which represent the collapsed implant shell floating inside the silicone gel, referred to as the &ldquo;linguine sign.&rdquo;",
"   </p>",
"   <p>",
"    The most important risk factor for silicone breast implant rupture is time since placement, since 50 percent of implants rupture after 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/42\">",
"     42",
"    </a>",
"    ]. The United States Food and Drug Administration (FDA) recommends that regular MRI screening be performed for asymptomatic women with silicone implants three years after implantation and every two years thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/43\">",
"     43",
"    </a>",
"    ]. However, there is little evidence to support a recommendation for regular MRI screening, which is expensive and may lead to anxiety and false positive results, and result in unnecessary surgery. Therefore, most experts agree that breast MRI should be used as a confirmatory diagnostic test and not be used to screen asymptomatic women for implant rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H633711\">",
"    <span class=\"h3\">",
"     Free silicone injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct injection of liquid silicone into the breast tissue for breast augmentation was done in the 1950&rsquo;s [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. This practice led to the development of painful hard silicone masses in the breast, termed silicone granulomas or siliconomas. Although this practice was banned by the FDA in the United States in 1965, free silicone injections were performed in other countries and women still present with sequelae of this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/46\">",
"     46",
"    </a>",
"    ]. Breast MRI is helpful in differentiating siliconomas from other breast masses because most silicone masses do not enhance with contrast administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376067\">",
"    <span class=\"h3\">",
"     Saline implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for breast MRI imaging to detect rupture of saline implants, as rupture results in rapid deflation of the implant and is easily detected on physical examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mammography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H21#H21\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Women with breast implants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3949769\">",
"    <span class=\"h2\">",
"     Detection of occult primary breast cancer in women with axillary metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast MRI is useful for detection of an occult primary breast cancer when a patient presents with metastatic disease in the axillary lymph nodes with no evident primary breast lesion. Several observational series have demonstrated that breast MRI can detect a primary breast cancer in the majority of women who present with axillary adenocarcinoma (",
"    <a class=\"graphic graphic_table graphicRef62800 \" href=\"UTD.htm?14/19/14652\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58055 \" href=\"UTD.htm?25/18/25888\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/14,33,47-58\">",
"     14,33,47-58",
"    </a>",
"    ]. The evaluation and treatment of women with occult primary breast cancer is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link\">",
"     \"Axillary node metastases with occult primary breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606323\">",
"    <span class=\"h2\">",
"     Preoperative evaluation of newly diagnosed breast cancer patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of MRI in women with newly diagnosed breast cancer is evolving and remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Nearly all invasive breast carcinomas enhance on gadolinium-enhanced MRI and breast MRI is better at depicting the extent of disease than mammography, ultrasound, or physical examination. Hence, MRI can detect occult ipsilateral and contralateral disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64751 \" href=\"UTD.htm?36/13/37072\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76575 \" href=\"UTD.htm?2/53/2901\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55600 graphicRef82069 \" href=\"UTD.htm?17/58/18343\">",
"     image 7A-B",
"    </a>",
"    ). In a retrospective review of 445 breast cancer patients, preoperative MRI detected an additional malignant lesion in 66 women (14.8 percent), including contralateral cancer in 4.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/59\">",
"     59",
"    </a>",
"    ]. A family history of breast cancer, an index diagnosis of intraductal carcinoma, and age &gt;67 years were associated with MRI detection of a contralateral cancer. However, a retrospective review of 45,453 women diagnosed with early stage breast cancer found that, after adjusting for patient and cancer characteristics, preoperative breast MRI did not reduce the incidence of multiple breast cancer related operations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major disadvantage of breast MRI is its limited specificity due to enhancement of benign breast lesions, which leads to additional biopsies, delays in treatment, and may contribute to an increased mastectomy rate. Guidelines for the incorporation of breast MRI in the preoperative assessment of women with suspected breast cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606330\">",
"    <span class=\"h2\">",
"     Measurement of response to neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant systemic therapy, also referred to as primary or preoperative systemic therapy, is the accepted approach for women with locally advanced breast cancer to reduce the size of the cancer and possibly allow for breast conservation. In most cases, response to treatment can be assessed with physical examination along with the breast imaging technique that most clearly showed the cancer at the time of diagnosis.",
"   </p>",
"   <p>",
"    There is increased interest in using breast MRI for assessment of the response to chemotherapy since decreases in lesion size and changes in enhancement kinetics correlate with pathologic response (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63203 \" href=\"UTD.htm?29/62/30694\">",
"     image 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. However, MRI has been shown to both overestimate and underestimate the amount of residual tumor after neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/66\">",
"     66",
"    </a>",
"    ]. A trial sponsored by the American College of Radiology Imaging Network (ACRIN) study 6657 is underway to study the use of MRI for the assessment of response to neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/67\">",
"     67",
"    </a>",
"    ]. Indications for neoadjuvant chemotherapy and the evaluation of response to treatment are discussed elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606337\">",
"    <span class=\"h2\">",
"     Differentiating postoperative changes from recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 15 percent of patients with breast cancer will develop a locoregional recurrence within 10 years of treatment with breast conserving therapy. Breast MRI can be used to differentiate surgical scarring and radiation changes from breast cancer recurrence in cases where the physical examination and imaging with mammography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasound is difficult to interpret (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74918 \" href=\"UTD.htm?2/62/3045\">",
"     image 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/13,68-70\">",
"     13,68-70",
"    </a>",
"    ]. Enhancement in the prior surgical site is suggestive of recurrence and merits core biopsy, while the absence of enhancement in the biopsy bed suggests fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/71\">",
"     71",
"    </a>",
"    ]. However, false positive readings can result from fat necrosis which also can enhance avidly.",
"   </p>",
"   <p>",
"    The recommendations for post-treatment surveillance and the management of locoregional recurrence after breast conserving therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=see_link\">",
"     \"Management of locoregional recurrence of breast cancer after breast conserving therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=see_link&amp;anchor=H12559900#H12559900\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606351\">",
"    <span class=\"h2\">",
"     Evaluation of inconclusive clinical or imaging findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast MRI can be used for the evaluation of equivocal findings on conventional imaging with mammography and ultrasound, such as focal asymmetry or a mammographic abnormality seen on only one view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54454 \" href=\"UTD.htm?39/4/40004\">",
"     image 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69798 graphicRef55041 \" href=\"UTD.htm?11/53/12121\">",
"     image 11A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/72\">",
"     72",
"    </a>",
"    ]. MRI may be helpful as an adjunct study to provide guidance for targeted ultrasound or core biopsy when localization would be difficult with conventional imaging alone. However, a negative MRI does not obviate the need for biopsy for suspicious findings on conventional imaging or physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/9,73\">",
"     9,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no data to support the use of breast MRI to evaluate patients with breast pain or patients with palpable lumps who have had normal mammography and sonography. Palpable breast lumps require biopsy for diagnosis. Conventional breast imaging techniques, the evaluation of breast pain and breast lumps, and the diagnostic approach to women with suspected breast cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=see_link\">",
"     \"Breast pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some have proposed breast MRI imaging for the evaluation of spontaneous nipple discharge when mammography and ultrasound of the periareolar area fail to identify a focal finding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/73-78\">",
"     73-78",
"    </a>",
"    ], we do not feel there is a role for MRI for this purpose. A negative MRI does not preclude disease and pathologic nipple discharge should be managed with a terminal duct excision. The evaluation and treatment of nipple discharge is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606358\">",
"    <span class=\"h2\">",
"     Screening high risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI has higher sensitivity for the detection of breast cancer in the high risk population than mammography or ultrasound and thus is recommended for screening women who are at significantly high risk (lifetime risk 20 percent or higher) for the development of breast cancer (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82565 \" href=\"UTD.htm?28/27/29104\">",
"     image 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/14,79-85\">",
"     14,79-85",
"    </a>",
"    ]. However, there is no evidence for a reduction in mortality or improved disease-free survival from screening with MRI, despite evidence that MRI can detect smaller cancers and more node-negative malignancies in high risk women than other imaging modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from major groups (including the National Comprehensive Cancer Network [NCCN] [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/33\">",
"     33",
"    </a>",
"    ] and the American Cancer Society [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/86\">",
"     86",
"    </a>",
"    ]) recommend a combination of annual mammography and breast MRI for breast cancer surveillance in women who are BRCA mutation carriers or those with significantly elevated risk of developing breast cancer. The optimal screening interval is not determined and while some centers perform annual mammography and breast MRI simultaneously, others alternate the two imaging studies at six month intervals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       BRCA mutation ���",
"      </strong>",
"      Women who have a proven mutation in one of the major susceptibility genes for breast cancer (BRCA mutations) or a family history of BRCA mutations are at a high risk of developing breast cancer. The testing for mutations in these genes is commercially available. Genetic testing for BRCA mutations is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       High BRCAPRO score",
"      </strong>",
"      ��� Women who have a strong family history with an estimated lifetime risk of breast cancer greater than 20 to 25 percent by BRCAPRO or equivalent risk models are at high risk of developing breast cancer. The assessment of familial risk for breast cancer is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       History of chest radiation ���",
"      </strong>",
"      Women who received chest irradiation, such as mantle radiation for Hodgkin lymphoma, are at significantly increased risk of breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link&amp;anchor=H25#H25\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Breast cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is insufficient data to support annual screening with MRI for women who are of lower, but still elevated risk, such as those with a personal history of breast cancer, dense breasts, or a prior benign biopsy revealing atypia. No evidence exists to support screening average risk women with breast MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link&amp;anchor=H14#H14\">",
"     \"Screening for breast cancer\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606365\">",
"    <span class=\"h1\">",
"     EMERGING IMAGING TECHNOLOGY FOR BREAST CANCER DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition of the limitations of mammography, ultrasound, and breast MRI has led to investigation of other breast imaging techniques including contrast-enhanced dual energy digital mammography, high-field strength MRI, magnetic resonance spectroscopy, diffusion weighted imaging, breast specific gamma imaging, and positron emission mammography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2782056\">",
"    <span class=\"h2\">",
"     Contrast-enhanced dual energy digital mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral dual-energy (DE) contrast-agent-enhanced (CE) digital mammography is a technique for detecting breast cancer that consists of high-energy and low-energy digital mammography following an intravenous injection of an iodinated contrast material [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/87\">",
"     87",
"    </a>",
"    ]. This technology may be a useful adjunct for patients who cannot undergo MRI evaluation (eg, claustrophobic, pacemaker). A prospective study that included 52 patients with a newly diagnosed breast cancer who underwent conventional mammography and an MRI followed by DE CE mammography found that MRI and DE CE mammography detected 50 (96 percent) of the index tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/88\">",
"     88",
"    </a>",
"    ]. Conventional mammography detected 42 cancers (81 percent). MRI detected 22 of 25 (88 percent) additional ipsilateral cancers while DE CE mammography detected 14 cancers (56 percent). An enhancing lesion identified on DE CE mammography was more likely to be malignant compared with enhancing lesions identified by MRI (positive predictive value 97 versus 85 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606381\">",
"    <span class=\"h2\">",
"     High field strength MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;High field strength magnets (3-Tesla and 7-Tesla) provide higher signal to noise ratios than conventional breast MRI, performed with 1.5-Tesla field strength magnets. The high field strength magnets result in higher spatial resolution and improved detection of breast cancers &lt;5 mm in size than conventional techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. However, there are no large prospective trials that show clinical advantage for high field strength MRI. In addition, the lack of widespread availability of higher field magnets limits applicability to clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606388\">",
"    <span class=\"h2\">",
"     Magnetic resonance spectroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR spectroscopy is a specialized MRI sequence that allows assessment of the chemical composition of tissue. Breast MR spectroscopy is designed to detect choline and its derivatives, based on the observation that malignant tumors have elevated choline levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/72,93\">",
"     72,93",
"    </a>",
"    ]. Choline is a molecule required for fatty acid synthesis during cell membrane production.",
"   </p>",
"   <p>",
"    MR spectroscopy may provide an adjunct to conventional breast MRI, with the potential to increase specificity and avoid benign biopsies in a substantial number of women. MR spectroscopy is also promising for the evaluation of non-mass like suspicious findings on breast MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/94\">",
"     94",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    However, MR spectroscopy misses some breast cancers, because not all express choline. In a study of 16 invasive ductal tumors; 88 percent had detectable choline peaks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/95\">",
"     95",
"    </a>",
"    ]. MR spectroscopy remains investigational, but it may have a future role in predicting outcome and monitoring response of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606395\">",
"    <span class=\"h2\">",
"     Diffusion weighted imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffusion weighted imaging is a noninvasive imaging technique that assesses the random motion of the water molecules in tissue, based on the observation that water diffusion is abnormal in breast cancers. The signal strength of water molecules is proportional to the degree of diffusion. The results of diffusion-weighted imaging are calculated and then reported with a quantitative measure termed the apparent diffusion coefficient (ADC) for the tissue being studied.",
"   </p>",
"   <p>",
"    Invasive breast cancers demonstrate restricted or less water&nbsp;diffusion than normal breast tissue or benign breast lesions, which results in a lower ADC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/72,98-100\">",
"     72,98-100",
"    </a>",
"    ]. A few observational studies have shown that diffusion-weighted imaging can differentiate benign from malignant breast lesions with equal sensitivity and greater specificity than MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While diffusion weighted imaging is promising for use in preoperative assessment of disease extent in breast cancer patients, the available data is limited and this technique cannot be used for screening asymptomatic women or to exclude breast cancer in patients with suspicious breast masses or abnormal mammography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606402\">",
"    <span class=\"h2\">",
"     Nuclear breast imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclear breast imaging techniques include breast-specific gamma imaging, positron emission tomography scanning, and positron emission mammography. These techniques provide a functional assessment of breast lesions at the cellular and metabolic level. Nuclear imaging techniques are limited by suboptimal spatial resolution of whole body cameras, hindering detection of small lesions. However, with the development of dedicated breast units, nuclear breast imaging has the potential to detect lesions less than 1 cm in size.",
"   </p>",
"   <p>",
"    Nuclear breast imaging techniques are promising for indications similar to those of breast MRI, including determination of disease extent, high risk screening, and monitoring response to therapy. However, there are limited data to justify the use of nuclear breast imaging techniques and they should be considered investigational. In addition, unlike MRI, nuclear breast imaging requires radiation exposure and radiation-related risks should be taken into consideration and discussed with the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606409\">",
"    <span class=\"h3\">",
"     Breast specific gamma imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast specific gamma imaging (BSGI) is a nuclear medicine imaging technique, using gamma cameras with 2 to 3 mm in-plane resolution in a mammographic configuration to provide images of the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. BSGI is based on the observation that breast cancers accumulate technetium-99m sestamibi in intracellular mitochondria. Intracellular mitochondria are present in greater numbers in breast cancer cells as compared to normal cells.",
"   </p>",
"   <p>",
"    BSGI is performed after intravenous injection of 25 mCi of technetium-99m sestamibi. The patient is imaged approximately 5 to 10 minutes following the injection of the radioisotope. Two scans are performed of each breast using mild compression for craniocaudal and mediolateral oblique views. Images should be correlated with the patient&rsquo;s mammograms, breast ultrasound and clinical breast examination. If a biopsy is necessary for a lesion not seen on other imaging modalities, a BSGI-compatible biopsy system is used to direct tissue sampling.",
"   </p>",
"   <p>",
"    In several observational studies, BSGI demonstrated equal sensitivity and greater specificity than MRI for the detection of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/108-113\">",
"     108-113",
"    </a>",
"    ]. While BSGI is promising for use in the preoperative assessment of disease extent in breast cancer patients, the available data are limited and this technique cannot be used for screening or to exclude breast cancer in patients with suspicious breast masses or abnormal mammography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10606416\">",
"    <span class=\"h3\">",
"     Positron emission tomography (PET) scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) scanning is a nuclear medicine imaging technique which produces a three-dimensional image. PET scanning for breast cancer detection is based on increased glucose metabolism in cancer cells as compared to normal tissue; hence malignancies can be detected with a radioactive tracer that reflects the process of increased glycolysis. A sugar, fluorine-18 labeled deoxyglucose (FDG), is used as the radioactive tracer for PET scanning because it is actively transported across the cell membrane, undergoes phosphorylation to FDG-6-phosphate, and is trapped within the cells. Tumor cells accumulate higher concentration of the tracer than normal cells, and are seen on the imaging scan as an area of enhancement.",
"   </p>",
"   <p>",
"    Because glucose is used as the radioactive tracer, patients must fast for four to six hours prior to injection to minimize cardiac uptake, and avoid strenuous activity for 24 hours prior to the study to minimize skeletal muscle uptake. A high-protein, low carbohydrate diet for 24 to 48 hours prior to imaging is also recommended, in an effort to minimize myocardial uptake of glucose. The patient's serum glucose should be less than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for optimal results.",
"   </p>",
"   <p>",
"    To prepare for the scan, the patient is injected intravenously with 10 to 15mCi of the isotope FDG, and allowed to rest quietly in a warm room. After the isotope circulates for 60 to 90 minutes, the imaging can be performed. Although malignancies take up the agent, false positives can result from any metabolically active process such as acute infection, radiation treatment, or trauma.",
"   </p>",
"   <p>",
"    A conventional positron emission tomography (PET) device does not have the spatial resolution to reliably detect primary breast malignancies less than 1 cm in size. PET scanning, with or without computed tomography (CT) image fusion, has been utilized in selected cases for staging of breast cancer for axillary and distant metastatic disease, evaluating patients with recurrence, and monitoring response to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/114-118\">",
"     114-118",
"    </a>",
"    ]. Routine post-treatment surveillance with PET scan in women treated for breast cancer is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=see_link&amp;anchor=H541712004#H541712004\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Role of laboratory and imaging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1930787\">",
"    <span class=\"h3\">",
"     Positron emission mammography (PEM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution fluorodeoxyglucose positron emission tomography with compression (positron emission mammography or PEM) is a modification of PET scanning, with 2 mm in-plane resolution, to improve detection of small malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. PEM is still investigational.",
"   </p>",
"   <p>",
"    For performance of PEM, patients are prepared as for PET. (See",
"    <a class=\"local\" href=\"#H10606416\">",
"     'Positron emission tomography (PET) scanning'",
"    </a>",
"    above.) Two scans are performed of each breast using mild compression for craniocaudal and mediolateral oblique views. Images should be compared with the patient&rsquo;s mammograms, breast ultrasounds and clinical breast exam. If a biopsy is necessary for a lesion not seen on other imaging modalities, a PEM-compatible biopsy system is used to direct tissue sampling.",
"   </p>",
"   <p>",
"    In several observational studies of breast cancer patients, PEM has 86 to 91 percent sensitivity and 91 to 93 percent specificity for detection of disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56543 \" href=\"UTD.htm?26/45/27346\">",
"     image 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/122-125\">",
"     122-125",
"    </a>",
"    ]. However, PEM does not reliably detect low grade malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/29/23002/abstract/117\">",
"     117",
"    </a>",
"    ]. Thus, while PEM is promising for the preoperative assessment of disease extent in breast cancer patients, PEM cannot be used for screening or to exclude breast cancer in patients with suspicious breast masses or abnormal mammography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1930703\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnetic resonance imaging (MRI) is used for breast cancer detection, assessment, and treatment monitoring, although appropriate indications, standardization of technique, and interpretation remain variable among facilities. MRI of the breast is also an important tool for the assessment of silicone implant integrity. (See",
"      <a class=\"local\" href=\"#H1930667\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of MRI for breast cancer detection is based on the concept of tumor angiogenesis or neovascularity. Tumor associated blood vessels have increased permeability, which leads to prompt take up and release of the contrast agent and helps to distinguish breast cancers from benign growths. (See",
"      <a class=\"local\" href=\"#H10606309\">",
"       'Breast MRI technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A dedicated breast coil should be used for breast MRI. The breast coil is designed to receive signals generated from breast tissue and permits imaging of both breasts simultaneously. (See",
"      <a class=\"local\" href=\"#H10606309\">",
"       'Breast MRI technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous gadolinium contrast must be used to maximize cancer detection and is administered during breast MRI to highlight neovascularity associated with cancers. Contrast is",
"      <strong>",
"       not",
"      </strong>",
"      necessary when the study is performed to evaluate silicone implant integrity. Gadolinium is contraindicated in patients with compromised renal function. (See",
"      <a class=\"local\" href=\"#H10606309\">",
"       'Breast MRI technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast MRI images are analyzed for morphology and initial and delayed contrast enhancement. Lesions are categorized as mass or non-mass lesions. The sensitivity of breast MRI is high, but the specificity is lower due to the overlap in the enhancement pattern of benign and malignant lesions. (See",
"      <a class=\"local\" href=\"#H1930682\">",
"       'MRI interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hormonal changes and cancer treatments can affect the accuracy of breast MRIs. Although there is variation in the performance of breast MRIs, reporting should follow standard guidelines. Facilities that perform breast MRI should have MRI-biopsy capability. (See",
"      <a class=\"local\" href=\"#H536410\">",
"       'Quality control considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contraindications for breast MRI include pregnancy, implanted devices and foreign bodies, and any prior history of gadolinium allergy or diminished renal function. (See",
"      <a class=\"local\" href=\"#H3948722\">",
"       'Precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The appropriate use of breast MRI is evolving and some indications remain controversial. Breast MRI has been used for the assessment of silicone implant integrity, diagnosis of occult primary breast cancers, determination of disease extent in newly diagnosed breast cancer patients, documentation of response to neoadjuvant chemotherapy, diagnosis of recurrence, clarification of inconclusive clinical or imaging findings and screening of high risk patients. (See",
"      <a class=\"local\" href=\"#H633667\">",
"       'Indications for breast MRI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recognition of the limitations of mammography, ultrasound, and breast MRI has led to investigation of other promising breast imaging techniques including high-field strength MRI, magnetic resonance spectroscopy, diffusion weighted imaging, breast specific gamma imaging, and positron emission mammography. (See",
"      <a class=\"local\" href=\"#H10606365\">",
"       'Emerging imaging technology for breast cancer detection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440138241\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Iuanow, who contributed to earlier versions of this topic review",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/1\">",
"      Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/2\">",
"      Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/3\">",
"      DeMartini WB, Ichikawa L, Yankaskas BC, et al. Breast MRI in community practice: equipment and imaging techniques at facilities in the Breast Cancer Surveillance Consortium. J Am Coll Radiol 2010; 7:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/4\">",
"      Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/5\">",
"      Pierce WB, Harms SE, Flamig DP, et al. Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress. Radiology 1991; 181:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/6\">",
"      Rubens D, Totterman S, Chacko AK, et al. Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast. AJR Am J Roentgenol 1991; 157:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/7\">",
"      Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/8\">",
"      Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995; 197:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/9\">",
"      Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/10\">",
"      Degani H, Gusis V, Weinstein D, et al. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 1997; 3:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/11\">",
"      Kinkel K, Helbich TH, Esserman LJ, et al. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol 2000; 175:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/12\">",
"      Khatri VP, Stuppino JJ, Espinosa MH, Pollack MS. Improved accuracy in differentiating malignant from benign mammographic abnormalities: a simple, improved magnetic resonance imaging method. Cancer 2001; 92:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/13\">",
"      Seely JM, Nguyen ET, Jaffey J. Breast MRI in the evaluation of locally recurrent or new breast cancer in the postoperative patient: correlation of morphology and enhancement features with the BI-RADS category. Acta Radiol 2007; 48:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/14\">",
"      DeMartini W, Lehman C. A review of current evidence-based clinical applications for breast magnetic resonance imaging. Top Magn Reson Imaging 2008; 19:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/15\">",
"      Baltzer PA, Benndorf M, Dietzel M, et al. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study. AJR Am J Roentgenol 2010; 194:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/16\">",
"      Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/17\">",
"      Pediconi F, Padula S, Dominelli V, et al. Role of breast MR imaging for predicting malignancy of histologically borderline lesions diagnosed at core needle biopsy: prospective evaluation. Radiology 2010; 257:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/18\">",
"      Linda A, Zuiani C, Furlan A, et al. Nonsurgical management of high-risk lesions diagnosed at core needle biopsy: can malignancy be ruled out safely with breast MRI? AJR Am J Roentgenol 2012; 198:272.",
"     </a>",
"    </li>",
"    <li>",
"     Londero V, Zuiani C, Linda A, Girometti R, Bazzocchi M, Sardanelli. High-risk breast lesions at inage-guided needle biopsy: Usefulness of MRI for treatment decision. AJR 2012;199:240.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/20\">",
"      M&uuml;ller-Schimpfle M, Ohmenha&uuml;ser K, Stoll P, et al. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997; 203:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/21\">",
"      Delille JP, Slanetz PJ, Yeh ED, et al. Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. Breast J 2005; 11:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/22\">",
"      Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997; 203:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/23\">",
"      Delille JP, Slanetz PJ, Yeh ED, et al. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations. Radiology 2005; 235:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/24\">",
"      Espinosa LA, Daniel BL, Vidarsson L, et al. The lactating breast: contrast-enhanced MR imaging of normal tissue and cancer. Radiology 2005; 237:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/25\">",
"      Talele AC, Slanetz PJ, Edmister WB, et al. The lactating breast: MRI findings and literature review. Breast J 2003; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/26\">",
"      Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 2007; 244:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/27\">",
"      Whitehouse GH, Moore NR. MR imaging of the breast after surgery for breast cancer. Magn Reson Imaging Clin N Am 1994; 2:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/28\">",
"      Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000; 6:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/29\">",
"      Taylor C, Georgian-Smith D. Regression of breast cancer in four patients treated with tamoxifen: mammographic features. AJR Am J Roentgenol 1994; 162:613.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology. American College of Radiology Breast Imaging Reporting and Data System BI-RADS, 4th ed, American Colege of Radiology, Reston, VA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/31\">",
"      D'Orsi CJ, Newell MS. BI-RADS decoded: detailed guidance on potentially confusing issues. Radiol Clin North Am 2007; 45:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/32\">",
"      Bassett LW, Dhaliwal SG, Eradat J, et al. National trends and practices in breast MRI. AJR Am J Roentgenol 2008; 191:332.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/34\">",
"      Teifke A, Lehr HA, Vomweg TW, et al. Outcome analysis and rational management of enhancing lesions incidentally detected on contrast-enhanced MRI of the breast. AJR Am J Roentgenol 2003; 181:655.",
"     </a>",
"    </li>",
"    <li>",
"     MRI safety. Institute for Magnetic Resonance Safety, Education, and Research Web site. file://222.MRIsafety.com (Accessed on February 06, 2008).",
"    </li>",
"    <li>",
"     MR safety. 2006. http//www.acr.org/SecondaryMainMenuCategories/quality_safety/MRSafety.aspx (Accessed on February 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/37\">",
"      Gorczyca DP, Gorczyca SM, Gorczyca KL. The diagnosis of silicone breast implant rupture. Plast Reconstr Surg 2007; 120:49S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/38\">",
"      Berg WA, Caskey CI, Hamper UM, et al. Diagnosing breast implant rupture with MR imaging, US, and mammography. Radiographics 1993; 13:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/39\">",
"      Everson LI, Parantainen H, Detlie T, et al. Diagnosis of breast implant rupture: imaging findings and relative efficacies of imaging techniques. AJR Am J Roentgenol 1994; 163:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/40\">",
"      Reynolds HE, Buckwalter KA, Jackson VP, et al. Comparison of mammography, sonography, and magnetic resonance imaging in the detection of silicone-gel breast implant rupture. Ann Plast Surg 1994; 33:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/41\">",
"      Brown SL, Silverman BG, Berg WA. Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis. Lancet 1997; 350:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/42\">",
"      Robinson OG Jr, Bradley EL, Wilson DS. Analysis of explanted silicone implants: a report of 300 patients. Ann Plast Surg 1995; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/43\">",
"      McCarthy CM, Pusic AL, Kerrigan CL. Silicone breast implants and magnetic resonance imaging screening for rupture: do U.S. Food and Drug Administration recommendations reflect an evidence-based practice approach to patient care? Plast Reconstr Surg 2008; 121:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/44\">",
"      Cher DJ, Conwell JA, Mandel JS. MRI for detecting silicone breast implant rupture: meta-analysis and implications. Ann Plast Surg 2001; 47:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/45\">",
"      Huch RA, K&uuml;nzi W, Debatin JF, et al. MR imaging of the augmented breast. Eur Radiol 1998; 8:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/46\">",
"      Scaranelo AM, de F&aacute;tima Ribeiro Maia M. Sonographic and mammographic findings of breast liquid silicone injection. J Clin Ultrasound 2006; 34:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/47\">",
"      Stomper PC, Waddell BE, Edge SB, Klippenstein DL. Breast MRI in the Evaluation of Patients with Occult Primary Breast Carcinoma. Breast J 1999; 5:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/48\">",
"      Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999; 212:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/49\">",
"      Buchanan CL, Morris EA, Dorn PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 2005; 12:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/50\">",
"      Olson JA Jr, Morris EA, Van Zee KJ, et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000; 7:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/51\">",
"      Chen C, Orel SG, Harris E, et al. Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer 2004; 5:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/52\">",
"      Obdeijn IM, Brouwers-Kuyper EM, Tilanus-Linthorst MM, et al. MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast. AJR Am J Roentgenol 2000; 174:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/53\">",
"      Schorn C, Fischer U, Luftner-Nagel S, et al. MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 1999; 9:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/54\">",
"      Henry-Tillman RS, Harms SE, Westbrook KC, et al. Role of breast magnetic resonance imaging in determining breast as a source of unknown metastatic lymphadenopathy. Am J Surg 1999; 178:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/55\">",
"      Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M. MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat 1997; 44:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/56\">",
"      Brenner RJ, Rothman BJ. Detection of primary breast cancer in women with known adenocarcinoma metastatic to the axilla: use of MRI after negative clinical and mammographic examination. J Magn Reson Imaging 1997; 7:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/57\">",
"      Morris EA, Schwartz LH, Dershaw DD, et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 1997; 205:437.",
"     </a>",
"    </li>",
"    <li>",
"     Fourquet, A, Meunier, et al. Occult primary cancer with axillary metastases. In: Diseases of the Breast, 3rd edition, Harris, JR, Lippman, ME, Morrow, M, Osborne, CK (Eds), Lippincott, Williams and Wilkins, Philadelphia 2004. p.1047.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/59\">",
"      Fan XC, Nemoto T, Blatto K, et al. Impact of presurgical breast magnetic resonance imaging (MRI) on surgical planning - a retrospective analysis from a private radiology group. Breast J 2013; 19:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/60\">",
"      Wang SY, Kuntz KM, Tuttle TM, et al. The association of preoperative breast magnetic resonance imaging and multiple breast surgeries among older women with early stage breast cancer. Breast Cancer Res Treat 2013; 138:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/61\">",
"      Pilewskie M, Kennedy C, Shappell C, et al. Effect of MRI on the management of ductal carcinoma in situ of the breast. Ann Surg Oncol 2013; 20:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/62\">",
"      Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004; 83:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/63\">",
"      Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005; 91:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/64\">",
"      Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005; 184:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/65\">",
"      Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003; 78:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/66\">",
"      Martincich L, Montemurro F, Cirillo S, et al. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. Radiol Med 2003; 106:51.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00043017 (Accessed on December 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/68\">",
"      Viehweg P, Heinig A, Lampe D, et al. Retrospective analysis for evaluation of the value of contrast-enhanced MRI in patients treated with breast conservative therapy. MAGMA 1998; 7:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/69\">",
"      Drew PJ, Kerin MJ, Turnbull LW, et al. Routine screening for local recurrence following breast-conserving therapy for cancer with dynamic contrast-enhanced magnetic resonance imaging of the breast. Ann Surg Oncol 1998; 5:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/70\">",
"      Rieber A, Merkle E, Zeitler H, et al. Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr 1997; 21:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/71\">",
"      Van Goethem M, Verslegers I, Biltjes I, et al. Role of MRI of the breast in the evaluation of the symptomatic patient. Curr Opin Obstet Gynecol 2009; 21:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/72\">",
"      Weinstein S, Rosen M. Breast MR imaging: current indications and advanced imaging techniques. Radiol Clin North Am 2010; 48:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/73\">",
"      Cilotti A, Iacconi C, Marini C, et al. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications. Radiol Med 2007; 112:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/74\">",
"      Nakahara H, Namba K, Watanabe R, et al. A comparison of MR imaging, galactography and ultrasonography in patients with nipple discharge. Breast Cancer 2003; 10:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/75\">",
"      Mortellaro VE, Marshall J, Harms SE, et al. Breast MR for the evaluation of occult nipple discharge. Am Surg 2008; 74:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/76\">",
"      Ballesio L, Maggi C, Savelli S, et al. Role of breast magnetic resonance imaging (MRI) in patients with unilateral nipple discharge: preliminary study. Radiol Med 2008; 113:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/77\">",
"      Tokuda Y, Kuriyama K, Nakamoto A, et al. Evaluation of suspicious nipple discharge by magnetic resonance mammography based on breast imaging reporting and data system magnetic resonance imaging descriptors. J Comput Assist Tomogr 2009; 33:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/78\">",
"      Morrogh M, Morris EA, Liberman L, et al. The predictive value of ductography and magnetic resonance imaging in the management of nipple discharge. Ann Surg Oncol 2007; 14:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/79\">",
"      Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007; 242:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/80\">",
"      Lehman CD, Isaacs C, Schnall MD, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007; 244:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/81\">",
"      Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:8469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/82\">",
"      Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/83\">",
"      Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003; 181:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/84\">",
"      Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/85\">",
"      Rijnsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010; 28:5265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/86\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/87\">",
"      Lewin JM, Isaacs PK, Vance V, Larke FJ. Dual-energy contrast-enhanced digital subtraction mammography: feasibility. Radiology 2003; 229:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/88\">",
"      Jochelson MS, Dershaw DD, Sung JS, et al. Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology 2013; 266:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/89\">",
"      Hecht EM, Lee RF, Taouli B, Sodickson DK. Perspectives on body MR imaging at ultrahigh field. Magn Reson Imaging Clin N Am 2007; 15:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/90\">",
"      Kuhl CK. Breast MR imaging at 3T. Magn Reson Imaging Clin N Am 2007; 15:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/91\">",
"      Elsamaloty H, Elzawawi MS, Mohammad S, Herial N. Increasing accuracy of detection of breast cancer with 3-T MRI. AJR Am J Roentgenol 2009; 192:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/92\">",
"      Pinker K, Grabner G, Bogner W, et al. A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol 2009; 44:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/93\">",
"      Sardanelli F, Fausto A, Di Leo G, et al. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol 2009; 192:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/94\">",
"      Bartella L, Thakur SB, Morris EA, et al. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007; 245:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/95\">",
"      Geraghty PR, van den Bosch MA, Spielman DM, et al. MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma. Breast J 2008; 14:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/96\">",
"      Mountford C, Ramadan S, Stanwell P, Malycha P. Proton MRS of the breast in the clinical setting. NMR Biomed 2009; 22:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/97\">",
"      Tozaki M, Sakamoto M, Oyama Y, et al. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 2008; 28:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/98\">",
"      Belli P, Costantini M, Bufi E, et al. Diffusion-weighted imaging in breast lesion evaluation. Radiol Med 2010; 115:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/99\">",
"      Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 2002; 16:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/100\">",
"      Sinha S, Lucas-Quesada FA, Sinha U, et al. In vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J Magn Reson Imaging 2002; 15:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/101\">",
"      Palle L, Reddy B. Role of diffusion MRI in characterizing benign and malignant breast lesions. Indian J Radiol Imaging 2009; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/102\">",
"      Tozaki M, Fukuma E. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy? AJR Am J Roentgenol 2009; 193:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/103\">",
"      Kim SH, Cha ES, Kim HS, et al. Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging 2009; 30:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/104\">",
"      Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/105\">",
"      Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/106\">",
"      Khalkhali I, Villanueva-Meyer J, Edell SL, et al. Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med 2000; 41:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/107\">",
"      O'Connor M, Rhodes D, Hruska C. Molecular breast imaging. Expert Rev Anticancer Ther 2009; 9:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/108\">",
"      Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. Radiology 2005; 237:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/109\">",
"      Brem RF, Floerke AC, Rapelyea JA, et al. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 2008; 247:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/110\">",
"      Brem RF, Petrovitch I, Rapelyea JA, et al. Breast-specific gamma imaging with 99mTc-Sestamibi and magnetic resonance imaging in the diagnosis of breast cancer--a comparative study. Breast J 2007; 13:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/111\">",
"      Brem RF, Fishman M, Rapelyea JA. Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol 2007; 14:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/112\">",
"      Brem RF, Ioffe M, Rapelyea JA, et al. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol 2009; 192:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/113\">",
"      Zhou M, Johnson N, Gruner S, et al. Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient. Am J Surg 2009; 197:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/114\">",
"      Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005; 11:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/115\">",
"      Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006; 24:5366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/116\">",
"      Cachin F, Prince HM, Hogg A, et al. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006; 24:3026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/117\">",
"      Avril N, Adler LP. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging. Radiol Clin North Am 2007; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/118\">",
"      Sch&ouml;der H, G&ouml;nen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 2007; 48 Suppl 1:4S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/119\">",
"      Raylman RR, Majewski S, Smith MF, et al. The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements. Phys Med Biol 2008; 53:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/120\">",
"      Weinberg IN. Applications for positron emission mammography. Phys Med 2006; 21 Suppl 1:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/121\">",
"      Tafra L. Positron Emission Tomography (PET) and Mammography (PEM) for breast cancer: importance to surgeons. Ann Surg Oncol 2007; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/122\">",
"      Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression (\"positron emission mammography\") is highly accurate in depicting primary breast cancer. Breast J 2006; 12:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/123\">",
"      Kumar R, Chauhan A, Zhuang H, et al. Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D: -glucose positron emission tomography: variations with age, breast density, and menopausal status. Mol Imaging Biol 2006; 8:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/124\">",
"      Levine EA, Freimanis RI, Perrier ND, et al. Positron emission mammography: initial clinical results. Ann Surg Oncol 2003; 10:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/29/23002/abstract/125\">",
"      Tafra L, Cheng Z, Uddo J, et al. Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. Am J Surg 2005; 190:628.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14972 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_23002=[""].join("\n");
var outline_f22_29_23002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1930703\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1930667\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10606309\">",
"      BREAST MRI TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1930682\">",
"      MRI INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6635177\">",
"      MRI of high-risk breast lesions identified by core biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H536410\">",
"      Quality control considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3948722\">",
"      PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H633667\">",
"      INDICATIONS FOR BREAST MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H633682\">",
"      Assessment of breast implants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H633704\">",
"      - Silicone implants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H633711\">",
"      - Free silicone injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376067\">",
"      - Saline implants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3949769\">",
"      Detection of occult primary breast cancer in women with axillary metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606323\">",
"      Preoperative evaluation of newly diagnosed breast cancer patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606330\">",
"      Measurement of response to neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606337\">",
"      Differentiating postoperative changes from recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606351\">",
"      Evaluation of inconclusive clinical or imaging findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606358\">",
"      Screening high risk women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10606365\">",
"      EMERGING IMAGING TECHNOLOGY FOR BREAST CANCER DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2782056\">",
"      Contrast-enhanced dual energy digital mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606381\">",
"      High field strength MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606388\">",
"      Magnetic resonance spectroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606395\">",
"      Diffusion weighted imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10606402\">",
"      Nuclear breast imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10606409\">",
"      - Breast specific gamma imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10606416\">",
"      - Positron emission tomography (PET) scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1930787\">",
"      - Positron emission mammography (PEM)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1930703\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440138241\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14972|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/13/39126\" title=\"diagnostic image 1\">",
"      Breast MRI invasive cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/24/18819\" title=\"diagnostic image 2\">",
"      Breast MRI extensive noninvasive cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/18/25888\" title=\"diagnostic image 3\">",
"      Breast MRI of occult primary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/39/29298\" title=\"diagnostic image 4\">",
"      Breast MRI of silicone implant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/13/37072\" title=\"diagnostic image 5\">",
"      Breast MRI of multifocal breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/53/2901\" title=\"diagnostic image 6\">",
"      Breast MRI of contralateral breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/34/31264\" title=\"diagnostic image 7A\">",
"      Breast MRI for evaluating extent of disease - case 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/4/24643\" title=\"diagnostic image 7B\">",
"      Breast MRI for evaluating extent of disease - case 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/62/30694\" title=\"diagnostic image 8\">",
"      Breast MRI documenting response to neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/62/3045\" title=\"diagnostic image 9\">",
"      Breast MRI of breast cancer recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/4/40004\" title=\"diagnostic image 10\">",
"      Mammographic occult breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/62/19425\" title=\"diagnostic image 11A\">",
"      Breast MRI of inconclusive mammographic findings - case 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/2/38950\" title=\"diagnostic image 11B\">",
"      Breast MRI of inconclusive mammographic findings - case 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/27/29104\" title=\"diagnostic image 12\">",
"      Breast MRI screening of BRCA carrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/45/27346\" title=\"diagnostic image 13\">",
"      Positron emission mammography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14972|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/2/24613\" title=\"figure 1\">",
"      Breast MRI of invasive ductal cancer kinetic color map",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/19/39227\" title=\"table 1\">",
"      BIRADS mammography categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/19/14652\" title=\"table 2\">",
"      Breast MRI mam occult breast CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=related_link\">",
"      Axillary node metastases with occult primary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=related_link\">",
"      Breast pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=related_link\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=related_link\">",
"      Physiology of lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_29_23003="Secondary hyperpara";
var content_f22_29_23003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of secondary hyperparathyroidism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Impaired calcitriol production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperphosphatemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased calcium intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Calcium malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin D deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bariatric surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancreatic disease (fat malabsorption)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Renal calcium loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic hypercalciuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Loop diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inhibiton of bone resorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bisphosphonates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hungry bone syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Prince RL. Secondary and tertiary hyperparathyroidism. In: Primer on the metabolic bone diseases and disorders of mineral metabolism,&nbsp;6th, Favus MJ (Ed), ASBMR, 2006. p. 191.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_23003=[""].join("\n");
var outline_f22_29_23003=null;
var title_f22_29_23004="Permissible fracture displacement for conservative treatment";
var content_f22_29_23004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Permissible fracture displacement for conservative treatment of phalangeal and metacarpal fractures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bone",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sub-location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Finger",
"       </td>",
"       <td class=\"subtitle1\">",
"        Angulation (degrees)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rotation (degrees)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Shortening (mm)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bony apposition (percentage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phalanx",
"       </td>",
"       <td>",
"        Shaft",
"       </td>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        Metacarpal",
"       </td>",
"       <td rowspan=\"4\">",
"        Neck",
"       </td>",
"       <td>",
"        Small",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ring",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Index",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Shaft",
"       </td>",
"       <td>",
"        Small",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ring",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Index",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_23004=[""].join("\n");
var outline_f22_29_23004=null;
var title_f22_29_23005="Pregnancy and pituitary size";
var content_f22_29_23005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Pregnancy increases pituitary volume",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pituitary volume, as assessed by mangetic resonance imaging, in the nonpregnant state and during pregnancy in 19- to 23-year-old normal women. There is a progressive increase in pituitary volume during pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gonzales JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging.&nbsp;Am J Med 1988; 85:217.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_23005=[""].join("\n");
var outline_f22_29_23005=null;
var title_f22_29_23006="Proximal tubule segments";
var content_f22_29_23006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal tubule segments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distribution of the S1, S2, and S3 segments defined by cell type in the proximal tubules from outer cortical (right) and juxtamedullary (left) nephrons.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Woodhall PB, Tisher CC, Simonton CA, Robinson RR, J Clin Invest 1978; 61:1320, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_29_23006=[""].join("\n");
var outline_f22_29_23006=null;
var title_f22_29_23007="Contents: Head and neck surgery";
var content_f22_29_23007=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Head and neck surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Head and neck surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         ENT",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/17/30999\">",
"           An overview of rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13801\">",
"           Anatomy and etiology of taste and smell disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/41/1690\">",
"           Approach to the adult with epistaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/32/43527\">",
"           Bad breath",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12823\">",
"           Cerumen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/49/34584\">",
"           Clinical presentation, diagnosis, and treatment of nasal obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/59/1977\">",
"           Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/42/37543\">",
"           Congenital anomalies of the larynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11608\">",
"           Differential diagnosis of a neck mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35397\">",
"           Ear barotrauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/6/26727\">",
"           Etiology and diagnosis of tinnitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/15/10490\">",
"           Etiology of hearing loss in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/16/8458\">",
"           Eustachian tube dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/1/18455\">",
"           Evaluation and treatment of taste and smell disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7558\">",
"           Evaluation of a neck mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18086\">",
"           Evaluation of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39429\">",
"           Evaluation of hearing loss in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18777\">",
"           Gingivitis and periodontitis in adults: Classification and dental treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/24/39300\">",
"           Hearing amplification in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16009\">",
"           Hoarseness in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/10/33960\">",
"           Laryngopharyngeal reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/58/26536\">",
"           Management of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/61/32729\">",
"           Meniere disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18824\">",
"           Motion sickness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11431\">",
"           Overview of craniofacial pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41896\">",
"           Presbycusis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/2/22568\">",
"           Salivary gland stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38296\">",
"           Sudden sensorineural hearing loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35176\">",
"           Tonsillectomy in adults: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/57/25495\">",
"           Treatment of tinnitus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Head and neck cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13013\">",
"           Cancer of the nasal vestibule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/40/7815\">",
"           Chordoma and chondrosarcoma of the skull base",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/57/23446\">",
"           Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/36/26184\">",
"           Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17525\">",
"           General principles of radiation therapy for head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/50/34602\">",
"           Head and neck sarcomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/28/19911\">",
"           Head and neck squamous cell carcinoma of unknown primary",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29946\">",
"           Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/34/11816\">",
"           Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/1/22554\">",
"           Management and prevention of complications of head and neck cancer during initial treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/45/8919\">",
"           Management of acquired maxillary defects: Prosthetic rehabilitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/42/30378\">",
"           Management of late complications of head and neck cancer and its treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39815\">",
"           Mandibular and palatal reconstruction in patients with head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28649\">",
"           Methods to overcome radiation resistance in head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30407\">",
"           Overview of head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36537\">",
"           Overview of the diagnosis and staging of head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/59/43959\">",
"           Overview of treatment for head and neck squamous cell cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/44/23241\">",
"           Paranasal sinus cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25719\">",
"           Postoperative radiation therapy in the management of head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/58/36775\">",
"           Posttreatment surveillance of squamous carcinoma of the head and neck",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/24/3466\">",
"           Quality of life in head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/23/38265\">",
"           Reirradiation for locally recurrent head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9927\">",
"           Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/41/28313\">",
"           Salivary gland tumors: Treatment of locoregional disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15270\">",
"           Second primary malignancies in patients with head and neck cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/51/31545\">",
"           Speech and swallowing rehabilitation of the patient with head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15459\">",
"           Squamous cell carcinoma of unknown primary site",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/27/34232\">",
"           Treatment of early (stage I and II) head and neck cancer: The hypopharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/4/20552\">",
"           Treatment of early (stage I and II) head and neck cancer: The larynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/29/32217\">",
"           Treatment of early (stage I and II) head and neck cancer: The oral cavity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/6/3174\">",
"           Treatment of early (stage I and II) head and neck cancer: The oropharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/3/8250\">",
"           Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/21/9559\">",
"           Treatment of locally recurrent head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/45/41689\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1321\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/55/15224\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40345\">",
"           Treatment of metastatic and recurrent head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16280\">",
"           Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39206\">",
"           Tumors of the nasal cavity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Head and neck infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6758\">",
"           Antibiotic failure in the treatment of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/3/21559\">",
"           Cervicofacial actinomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/30/27110\">",
"           Complications of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36569\">",
"           Deep neck space infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5738\">",
"           Evaluation of acute pharyngitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35178\">",
"           Tonsillectomy and adenoidectomy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35176\">",
"           Tonsillectomy in adults: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6761\">",
"           Tonsillectomy in adults: Surgery",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sleep apnea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/48/2826\">",
"           Management of obstructive sleep apnea in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40217\">",
"           Management of obstructive sleep apnea in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/46/32489\">",
"           Evaluation and management of dental injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/47/24309\">",
"           Evaluation and repair of tongue lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/49/7962\">",
"           Facial trauma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6615\">",
"           Jaw fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/50/33575\">",
"           Nasal trauma and fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9783\">",
"           Orbital fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-0ABC9FDC8A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_29_23007=[""].join("\n");
var outline_f22_29_23007=null;
       